



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmjjournals.org>).

If you have any questions on BMJ Open's open peer review process please email
info.bmjopen@bmj.com

BMJ Open

The effect of desflurane, sevoflurane, or propofol on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery: study protocol for a prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2024-092611
Article Type:	Protocol
Date Submitted by the Author:	19-Aug-2024
Complete List of Authors:	Taschner, Alexander; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Sinner, Barbara; Medical University Innsbruck, Department of Anaesthesia and Intensive Care Eckhardt, Christine; Medical University Innsbruck, Department of Anaesthesia and Intensive Care Adamowitsch, Nikolas; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Hantakova, Nicole; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Hochreiter, Beatrix; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Zotti, Oliver; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Reiterer, Christian; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Fleischmann, Edith; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Kabon, Barbara; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Horvath, Katharina; Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine Fraunschiel, Melanie; Medical University of Vienna, IT Services and strategic information management Graf, Alexandra; Medical University of Vienna, Institute of Medical Statistics, Centre for Medical Data Science
Keywords:	Delirium, Adult anaesthesia < ANAESTHETICS, ANAESTHETICS

SCHOLARONE™
Manuscripts

1
2
3
4
5 **The effect of desflurane, sevoflurane, or propofol on the incidence of postoperative delirium in**
6 **older adults undergoing moderate- to high-risk major noncardiac surgery: study protocol for a**
7
8 **prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)**

9
10
11
12
13
14
15
16
17 Alexander Taschner¹; Edith Fleischmann¹; Barbara Kabon¹; Barbara Sinner²; Christine Eckhardt²;
18 Katharina Horvath¹; Nikolas Adamowitsch¹; Nicole Hantakova¹; Beatrix Hochreiter¹; Oliver Zotti¹;
19
20 Melanie Fraunschiel³; Alexandra Graft⁴; Christian Reiterer^{1*} for the RAPID-II investigator group
21
22
23 (eAppendix 1 in the Online Supplement)

24
25
26
27
28
29
30 ¹ Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of
31
32 Vienna, 1090 Vienna, Austria

33
34 ² Department of Anaesthesia and Intensive Care, Medical University Innsbruck, 6020 Innsbruck,
35
36 Austria

37
38 ³ IT Services and strategic information management, Medical University of Vienna, 1090 Vienna,
39
40 Austria

41
42 ⁴ Institute of Medical Statistics, Centre for Medical Data Science, Medical University of Vienna, 1090
43
44 Vienna, Austria

45
46 * Correspondence to:

47
48 Prof. Christian Reiterer, M.D., Ph.D.

49
50 Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of
51
52 Vienna; Spitalgasse 23, 1090 Vienna, Austria.

53
54 christian.reiterer@meduniwien.ac.at; Phone: 0043 1 40400 20760

55
56 Word count: 4309 words

Abstract

Introduction: The effect of different anaesthetics on the incidence of postoperative delirium is still not entirely clear. Therefore, we will evaluate the effect of desflurane versus sevoflurane versus propofol for maintenance of anaesthesia on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery. We will further compare the incidences of delayed neurocognitive recovery, long-term postoperative neurocognitive disorder, postoperative nausea and vomiting between the groups.

Methods and analysis: In this multi-centre, prospective, observer-blinded, randomised controlled clinical trial we will include 1332 patients ≥ 65 years of age undergoing moderate- to high-risk major noncardiac surgery lasting at least two hours. Patients will be randomly 1:1:1 assigned to receive desflurane, sevoflurane or propofol for anaesthesia. Maintenance of anaesthesia will be performed in a goal-directed manner using processed electroencephalography with an intraoperative goal of bispectral index 50 ± 10 . Our primary outcome will be the incidence of postoperative delirium within the first five postoperative days. Postoperative delirium will be assessed using the 3D-Confusion Assessment Method (3D-CAM) or CAM-ICU in the morning and evening of the first five postoperative days by blinded study personnel. The primary outcome, the incidence of postoperative delirium, will be compared between the three study groups using a Chi-Square-test. Furthermore, a logistic regression model for the incidence of postoperative delirium will be performed accounting for randomised group as well as other pre-defined confounding factors.

Ethics and dissemination: This clinical trial has been approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria. The results of this trial will be published in a peer-reviewed journal.

Trial registration:

ClinicalTrials.gov NCT05990790;

<https://clinicaltrials.gov/study/NCT05990790?term=NCT05990790&rank=1>

Strengths and limitations of this study:

- This will be a properly powered multi-centre prospective trial to compare the effects of three commonly used anaesthetics on the incidence of postoperative delirium.
- This trial will achieve good internal validity due to randomisation and blinding of outcome assessors as well as high external validity due to the large sample size and the inclusion of many types of noncardiac surgery.
- Postoperative delirium will be assessed in the morning and evening for the initial five postoperative days according to the current recommendations.
- Due to the different methods of administration of the three anaesthetics, blinding of the attending anaesthetists will not be performed.

Introduction

Postoperative delirium is a major complication after cardiac and noncardiac surgery and occurs more often in older adults.^{1–3} Based on previous observational studies, the incidence of postoperative delirium in older adults is between 20 and 45%.^{4–6} Delirium is associated with prolonged stay in intensive care units (ICU) and hospitalisation, leading to higher hospitalisation costs, which are as high as costs caused by cardiovascular complications.^{4,5,7,8} More importantly, postoperative delirium is associated with accelerated long-term neurocognitive decline and dementia and further increases morbidity and mortality.^{4,5,9–12} In this context, the American College of Surgeons and the American Society of Anesthesiologists have identified the prevention of postoperative delirium as a public health priority.^{8,10} Nevertheless, a clear consensus on perioperative anaesthesiologic management of older adults undergoing major noncardiac surgery with the specific goal of preventing postoperative delirium has not been established yet.¹⁰

Some previous studies evaluated the effects of volatile versus intravenous anaesthesia on the incidence of postoperative delirium.^{13–16} However, these studies mostly compared sevoflurane versus propofol anaesthesia and showed conflicting results.^{13–16} The most recent and largest randomised trial showed a significantly lower incidence of postoperative delirium after propofol-anaesthesia as compared to sevoflurane-anaesthesia.¹⁶ However, so far data regarding the effects of desflurane as compared to sevoflurane and propofol on the incidence of postoperative delirium is scarce. While it has been shown previously that desflurane anaesthesia leads to significantly faster immediate postoperative recovery as compared to sevoflurane,^{17–21} we could not observe in one of our previous studies a significant difference immediate postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery.²² Nevertheless, the effect of desflurane versus sevoflurane versus propofol on the incidence of postoperative delirium in older adults undergoing major noncardiac surgery is still unclear.

Therefore, we will test our primary hypothesis that anaesthesia with desflurane will be associated with a significantly lower incidence of postoperative delirium within the first five postoperative days as compared to anaesthesia with sevoflurane or anaesthesia with propofol in older adults undergoing

moderate- to high-risk major noncardiac surgery lasting at least two hours. We will further test the secondary hypotheses that anaesthesia with desflurane will be associated with significantly lower incidences of delayed neurocognitive recovery and long-term neurocognitive disorder as compared to anaesthesia with sevoflurane or anaesthesia with propofol.

Methods and Analysis

Trial Design

We will conduct the RAPID-II trial, a multi-centre, observer-blinded, prospective, randomised, three-arm parallel arm clinical trial at the Medical University of Vienna and the Medical University Innsbruck. All members of the RAPID-II investigator group are listed in Online Supplement 1. We will include 1332 patients ≥ 65 years of age undergoing moderate- to high-risk major noncardiac surgery. The trial was approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria on the 19th of June 2023. We started patient enrolment on the 3rd of September 2023.

The RAPID-II trial will test the primary hypothesis that general anaesthesia with desflurane will result in a significant reduction in the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery as compared to general anaesthesia with sevoflurane. We further test that general anaesthesia with desflurane will result in a significant reduction in the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery as compared to general anaesthesia with propofol.

Study population

The inclusion and exclusion criteria are presented in Table 1. Study personnel will screen the surgical schedule the day before surgery and check for eligibility. Definitions of surgeries, which will be included are listed in eAppendix 2 of the Online Supplement. They will further approach eligible patients to obtain informed consent before surgery. Previous experience showed that 6-8 patients will be eligible per week. Therefore, we assume a period of 3-4.5 years to complete patient recruitment for this study.

Data management

Electronic data will be recorded in the data management system “Clincase”, Version 2.7.0.12 hosted by IT Services & strategic information management of the Medical University of Vienna, Vienna, Austria.

Randomisation and blinding

We will randomise patients within one hour before surgery. We will use the online randomisation programme “Randomizer” (Randomizer, Medical University of Graz, Graz, Austria: <https://www.meduniwien.ac.at/randomizer/web/login.php>) provided by the IT Services & strategic information management Department of the Medical University of Vienna, 1090 Vienna, Austria. Randomisation will be performed with permuted blocks stratified by study centre, sex, and age (65-79 years, ≥ 80 years). Randomisation will only be performed by registered personnel, who are not involved in postoperative outcome assessments. The attending anaesthetists will be informed about the randomly assigned group and will not be involved in postoperative outcome assessments. Only study personnel responsible for postoperative outcome assessments will be blinded regarding the randomly assigned group. Patients will be randomised 1:1:1 to the following three groups:

Desflurane group: after induction of anaesthesia, anaesthesia will be maintained with goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50 ± 10 .

Sevoflurane group: after induction of anaesthesia, anaesthesia will be maintained with goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50 ± 10 .

Propofol group: after induction of anaesthesia, anaesthesia will be maintained with a goal-directed continuous infusion of propofol with an intraoperative goal of bispectral index (BIS) 50 ± 10 .

Anaesthesia protocol

All patients will receive an ECG, blood pressure and peripheral oxygen saturation monitoring. An arterial line and/or central venous line will be placed and monitored at the discretion of the attending anaesthetist according to local clinical standard of care.

After endotracheal intubation, anaesthesia will be maintained using desflurane or sevoflurane in a mixed oxygen carrier gas or continuous propofol infusion according to the allocated randomised group. We will use the first 10 minutes after intubation to set anaesthesia to the target BIS value. Desflurane, sevoflurane and propofol respectively will be titrated and adjusted using processed electroencephalography for a target BIS of 50 ± 10 throughout surgery.

Fentanyl and remifentanil, respectively, will be administered at the discretion of the attending anaesthetist. We will give additional muscle relaxation to maintain 1-2 mechanical twitches in response

1
2
3 to supra-maximal stimulation (Train-of-four stimulation, target <75%). For mechanical ventilation, we
4 will maintain an inspiratory FiO₂ between 0.3 and 0.5 to achieve a SpO₂ of at least 93% or pO₂ of
5 >80mmHg. Tidal volumes will be set between 6 and 8mL lean body weight to maintain end-tidal CO₂
6 within 35-40mmHg. Positive end-expiratory pressure will be set at 5mmHg or higher according to the
7 patients' requirements. Intraoperative PONV prophylaxis will be administered at the discretion of the
8 attending anaesthetist. We will actively warm patients with convective warming to maintain
9 perioperative normothermia. Intraoperative mean arterial pressure will be held at a minimum of
10 65mmHg. Intraoperative fluid and vasopressor management will be performed at the discretion of the
11 attending anaesthetist according to local clinical standard of care. We will maintain a haemoglobin of at
12 least 8g.dL⁻¹. Anaesthesiologic adjuvants, e.g. esketamine, clonidine, atropine, dexmedetomidine,
13 midazolam, and scopolamine should be avoided. The postoperative management of medication will be
14 done according to the attending physicians.

15
16 At the end of surgery, we will stop the administration of desflurane, sevoflurane, and propofol
17 respectively. In the case of planned intubated transfer to intensive care units (ICU) after surgery,
18 desflurane or sevoflurane will be stopped and propofol administration will be started (Figure 1).

37 Outcomes

38 Our primary outcome will be the incidence of postoperative delirium within the first five postoperative
39 days between the desflurane, sevoflurane, and propofol groups.

40 Our secondary outcomes will include the incidence of delayed neurocognitive recovery, postoperative
41 need of supplemental oxygen, length of stay in the ICU, incidence of postoperative nausea and vomiting
42 (PONV) in the early and late postoperative periods, intraoperative hypotension, and death within the
43 first five postoperative days.

44 Our exploratory outcomes will include the number of days at home up to 30 days after surgery, long-
45 term postoperative neurocognitive disorder one year after surgery, and postoperative area under the
46 curve of plasma concentrations of inflammatory biomarkers (C-reactive protein (CRP), Interleukin-6
47 (IL-6), Procalcitonin (PCT)), cardiac biomarkers (Troponin T, N-terminal pro-brain natriuretic peptide
48 (NT-proBNP)) and other biomarkers.

(NT-proBNP), Copeptin), and neuronal injury biomarkers (S100-B, Neuron-specific enolase (NSE)).

Furthermore, we will assess one-year all-cause mortality one year after surgery in all patients.

In a sub-study, we will compare differences between preoperative and postoperative concentrations of advanced neuro-biomarkers including neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) between the groups.

A detailed description of primary, secondary, exploratory, and sub-study specific outcomes and their assessments is shown in Table 2.

Measurements

Demographic and morphometric data

Basic data including age, sex, body mass index, and ASA physical status, will be recorded. We will record medical history including comorbidities, long-term medication, and history of tobacco or alcohol use and type of surgery.

Perioperative data

Routine intra- and postoperative anaesthesia specific data will be extracted from our electronic anaesthesia records. Intraoperative data will include arterial blood gas analysis, durations of anaesthesia and surgery, intraoperative fluid management, intraoperative medication, vasopressors, and haemodynamic data.

We will further record inspiratory and expiratory concentrations of the administered volatile anaesthetic and intraoperative amount of propofol. Intraoperative BIS data (BISTM, Medtronic[®], Meerbusch, Germany) including BIS values and density spectral array (DSA) will be recorded and extracted directly from the BIS monitor.

Postoperative pain will be recorded based on the numeric pain rating scale (NRS) in the PACU, ICU, and on the ward twice daily within the first five postoperative days. We will record the overall amount of piritramide, non-steroidal analgesics, duration of epidural anaesthesia, and the amount of co-analgesics administered at the PACU, ICU, or on the ward within the first five postoperative days.

Outcome measurements

All postoperative outcome assessments will be performed by trained study personnel, who are blinded to the assigned randomised group.

For our primary outcome, we will perform the 3D-confusion assessment method (3D-CAM) evaluations starting on the evening of the day of surgery (6 p.m.–10 p.m.). Following 3D-CAM evaluations will be performed twice daily – in the mornings (5 a.m.–11 a.m.) and evenings (6 p.m.–10 p.m.) for the following five postoperative days if patients are still hospitalised.^{23,24} In patients in the ICU, we will perform CAM-ICU evaluations.^{23,24}

For the assessment of delayed neurocognitive recovery, we will perform digit symbol substitution tests (DSST), trail making test (TMT) part A and part B before surgery and on the fifth postoperative day if the patients are still hospitalised.^{25,26} For the TMT the time until test completion and the number of mistakes will be recorded. If the patients are intubated on the fifth postoperative day, the assessments will be postponed for two days. For the assessment of neurocognitive disorder, we will further perform an adapted Montreal Cognitive Assessment (MoCA) test (telephone MoCA) before surgery and one year after surgery.^{27–30} DSST, TMT, 3D-CAM, CAM-ICU, and MoCA tests will be performed only by trained and blinded study personnel. PONV will be assessed on the evening of the day of surgery and in the morning and evening of the following five days. PONV will be defined as subjective symptoms of nausea and/or occurrence of vomiting at each timepoint. Oxygen supplementation will be recorded by number of litres.minute⁻¹ oxygen administered for SpO₂ ≥93% at PACU or ICU respectively. Furthermore, we will record the intraoperative use of vasopressors. We will record the duration of stay in the ICU in all patients. Phone follow-ups will be performed in all patients 30 days after surgery to determine the number of days at home up to 30 days after surgery and one year after surgery to perform the MoCA tests.

Study specific blood samples will include CRP, IL-6, PCT, Troponin T, NT-proBNP, Copeptin, NSE, S100-B, NfL, and GFAP. All laboratory parameters will be measured at the Department of Laboratory Medicine at the Medical University of Vienna and at the Department of Laboratory Medicine at the Medical University Innsbruck respectively. Blood samples will be treated with standard of care to provide best accuracy of measurement. Study specific blood samples of CRP, IL-6, PCT, Troponin T,

1
2 NT-proBNP, Copeptin, NSE, and S100-B will be drawn shortly before induction of anaesthesia, within
3 two hours after surgery and on the second postoperative day. Sub-study specific blood samples of NfL
4 and GFAP will be collected shortly before induction of anaesthesia and on the third postoperative day.
5 Sub-study specific blood samples will then be centrifuged and stored.
6
7
8
9
10

11 12 13 *Statistical analysis*

14 Data analysis

15 Baseline characteristics such as age, sex, ASA physical status, history of tobacco use, comorbidities,
16 long-term medication, and type of surgery will first be analysed descriptively. Descriptive statistics will
17 be calculated overall and separately for the three groups. Continuous variables will be summarised using
18 means, standard deviations, median, and interquartile ranges. Categorical data will be summarised using
19 absolute numbers and percentages.
20
21

22 Our primary outcome, the incidence of postoperative delirium, will be described in a descriptive way
23 using absolute numbers and percentages per study group. First, we will compare the incidence of
24 postoperative delirium between the three groups using a Chi-Square-test. Furthermore, a logistic
25 regression model for the incidence of postoperative delirium will be performed accounting for
26 randomised group as well as other confounding factors (e.g. age, BMI, ASA physical status, duration of
27 anaesthesia, additional epidural/regional anaesthesia, history of cerebrovascular disease). All three
28 groups will be analysed together in the logistic regression model and the pairwise comparison will be
29 conducted within the model. Patients, who die within the first five postoperative days will be excluded
30 from the primary analysis of our trial. As sensitivity analysis, to additionally account for death within 5
31 days after surgery, a logistic regression model for the probability of the combined endpoint
32 (postoperative delirium or death) will be performed accounting for randomised group and other possible
33 confounding factors. Significance levels for the primary outcome will be used as described in the sample
34 size calculation section to account for the two interim analyses and the pairwise group comparisons to
35 retain an overall level for the type I error of 0.05
36
37

38 The secondary outcome, the incidence of delayed neurocognitive recovery, will be evaluated between
39 the study groups using a Chi-Square-test. Furthermore, a logistic regression model for the probability of
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 delayed neurocognitive recovery will be performed accounting for randomised group as well as other
3 possible confounding factors.
4

5 The secondary outcome, the number of litres of administered supplemental oxygen in PACU or ICU to
6 achieve a $\text{SpO}_2 \geq 93\%$ will be compared between the study groups using Mann-Whitney-U tests.
7

8 The secondary outcome, the length of stay in the ICU, will be compared between the groups using a
9 competing risk model for time to discharge from ICU and death as competing event accounting for study
10 group as well as other possible confounding factors.
11

12 The secondary outcomes, incidences of PONV in the early and late postoperative period, will be
13 evaluated between the groups using Chi-Square-tests. Furthermore, logistic regression models for the
14 incidences of PONV in the early and late postoperative period will be performed.
15

16 The secondary outcome, intraoperative duration of MAP $<65\text{mmHg}$ and the overall intraoperatively
17 administered amount of catecholamines, will be compared between the groups using Mann-Whitney-U
18 tests.
19

20 The secondary outcome, death within five days after surgery, will be compared between the groups
21 using a Chi-Square-test. Furthermore, a logistic regression model for the probability of death will be
22 performed.
23

24 The exploratory outcome, number of days at home up to 30 days after surgery, will be compared between
25 the groups using Mann-Whitney-U tests. The exploratory outcome, incidence of neurocognitive
26 disorder, will be compared using Chi-Square-tests. As exploratory outcomes, area under the curves of
27 perioperative inflammatory biomarkers, cardiac biomarkers, and neuronal injury biomarkers, will be
28 calculated and compared between the groups using Mann-Whitney-U tests. Lastly, probability of all-
29 cause death within one year after surgery will be presented between the groups using Kaplan-Meier
30 curves. For secondary and exploratory outcomes, a significance level of 0.05 is used.
31

32 Sample size calculation

33

34 We estimated the number of patients required for this trial based on previous studies, which showed that
35 the incidence of postoperative delirium in older adults undergoing major abdominal surgery lies between
36 5-50%,^{5,31,32} whereas the largest study reported an incidence of 25%.³³ Using a conservative approach,
37

we assumed the incidence of postoperative delirium at about 25%. A reduction of 10% points was assumed to be clinically relevant (25% versus 15%).

Two interim analyses, one after 1/3 and one after 2/3 of recruitment are pre-planned. To correct for the comparison of the three groups, Bonferroni-correction was applied resulting in a two-sided overall significance level of 0.0167 (0.05/3 for three comparisons). To further correct for the two interim-analyses (three total analyses including final analysis), the Hwang-Shih-DeCani spending function for group sequential designs (with associated parameter -4) was used resulting in a nominal alpha level of 0.001 for the first interim analysis, 0.004 for the second interim analysis, and 0.015 for the final analysis to control the overall significance level of 0.0167 for each of the three group comparisons.

Using a group sequential z-test and assuming an odds ratio of 0.529 (for proportions of 0.25 as compared to 0.15), we calculated a needed sample size of 431 patients per group to achieve a power of 0.9. We assumed a drop-out rate of 3% (including patients, who die within the first five postoperative days), resulting in a needed sample size of 1332 patients (444 patients per group).

The sample size calculation was performed using NQuery 8.

Data safety monitoring board

The following experienced researchers will comprise the Data Safety Monitoring Board (DSMB): Prof. Dr. Eva Base (Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of Cardiothoracic and Vascular Anaesthesia, Medical University of Vienna, Austria), Prof. Dr. Michael Wolzt (Department of Clinical Pharmacology, Medical University of Vienna, Austria), Prof. Dr. Markus Zeitlinger (Department of Clinical Pharmacology, Medical University of Vienna, Austria), Prof. Dr. Gerd Silberhumer (Department of General Surgery, Medical University of Vienna, Austria).

Patients' safety will be monitored through the data and safety monitoring board. The DSMB will evaluate adverse events (AEs, SAEs, SUSARs, ADR) for the two pre-planned interim analyses. In detail, the DSMB will evaluate adverse events from 444 patients and 888 patients after all data are available. It will be the responsibility of this committee to alert the local ethics committee via letter of any harmful effects in one of the study groups. This committee, along with the local ethics committee will have the

1
2
3 exclusive authority to stop the study either for futility, harm, or clear benefit. Any morbidity potentially
4 related to the study protocol will be reported to the ethics committee.
5
6
7
8
9

10 *Emergency unblinding and termination of the study drug*

11 Attending anaesthesiologists will not be blinded for respective anaesthetic agents. In the case of
12 discontinuation or change of the randomly assigned group, assessments of postoperative outcomes will
13 be continued according to the study protocol and patients will not be dropped out because of intention
14 to treat. In the case an adverse event or a serious adverse event occurs, the blinded outcome assessor
15 will inform the principal investigator or responsible study personnel immediately.
16
17
18
19
20
21
22
23

24 *Termination of the study*
25

26 In the case of a preterminal termination of the study because of significant incidence of adverse events
27 evaluated by the DSMB, the sponsor (Medical University of Vienna) will notify the competent
28 authorities the end of the study including an appropriate justification. If the study will be terminated
29 because of safety reasons the European Medicines Agency (EMA) will be notified as well.
30
31
32
33
34
35
36

37 *Data monitoring*
38

39 Data monitoring will be performed by the Clinical Trials Coordination Centre of the Medical University
40 of Vienna. The designated monitor will contact and visit the investigator on a regular basis and will be
41 allowed to have direct access to all source documents, which are needed to verify all CRF and eCRF
42 entries and other protocol-related documents provided that subject confidentiality is maintained in
43 agreement with legal regulations. It will be the monitors' responsibility to inspect the CRFs and eCRFs
44 at regular intervals according to the monitoring plan throughout the study, to verify the adherence to the
45 protocol and the completeness, consistency, and accuracy of the data being entered on them.
46
47
48
49
50
51
52
53
54
55

56 *Data Safety*
57

58 All hard-copy forms, such as CRFs, source data and informed consents will be stored in locked rooms
59 within a secured area and are only accessible by investigators involved in the trial.
60

1
2
3 Access to data is strictly controlled and will only be provided to the sponsor (Medical University of
4 Vienna), the study investigators, ethics committee (Ethic committee of the Medical University of
5 Vienna), and if requested the Austrian Competent Authorities (Bundesamt für Sicherheit im
6 Gesundheitswesen (BASG)).
7
8
9
10

11 Data will be stored after publishing of the trial and all of the sub-studies by Iron Mountain Austrian
12 Archivierungs GmbH (Gewerbeparkstraße 3, 2282 Markgrafneusiedl, Austria) for a period of not less
13 than twenty-five years in accordance with the Conduct of a Clinical Trial (ICH E6 Section 8) and as
14 required by the national laws.
15
16
17
18

19
20
21
22 *Patient and Public involvement*
23
24 No patient or public involvement.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The RAPID-II trial will provide clinical evidence regarding the effects of desflurane, sevoflurane, and propofol on postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery.

The most recent and largest trial in over 1200 patients demonstrated that propofol-based anaesthesia was associated with a lower incidence of postoperative delirium within the first five days as compared to sevoflurane-based anaesthesia.¹⁶ However, they further showed that the long-term cognitive function – assessed via telephone interviews – was significantly better in the sevoflurane group as compared to the propofol group three years after surgery.¹⁶ Cao et al. suggested that the choice of isoflurane or desflurane instead of sevoflurane would have led to similar results.¹⁶ Nevertheless, it has to be emphasized that this is not based on any scientific evidence.

In fact, pharmacokinetic characteristics of desflurane lead to significantly faster elimination as compared to sevoflurane.^{34–36} Desflurane has a blood/gas coefficient of 0.45, which is the lowest of all available volatile anaesthetics.³⁴ Thus, the context-sensitive decrement time of desflurane is significantly faster as compared to sevoflurane.^{35,36} Specifically, the time until 90% of sevoflurane is eliminated increases significantly after two hours of administration, while the time of elimination of 90% of desflurane remains relatively constant.^{35,36} Some studies have shown that desflurane led to significantly faster extubation times, faster eye opening to verbal command, faster reciting of full name, and faster orientation as compared to sevoflurane.^{17–21} Furthermore, a recent pilot study showed that in patients, who received desflurane for major surgery, postoperative cognitive function assessed via Mini Mental State Examination (MMSE) was significantly higher after desflurane anaesthesia as compared to sevoflurane.³⁷ Interestingly, studies investigating different anaesthetics with a clinical meaningful neurological outcome are still lacking, specifically in regards to desflurane. Thus, the strength of our trial is that it will be the first adequately powered randomised study comparing the effects of desflurane on the incidence of postoperative delirium as compared to sevoflurane or propofol.

In addition, measuring anaesthetic depth by simply using the BIS value is not sufficient. In the study by Cao et al. only 70% of patients were monitored with BIS and the BIS values and not raw EEG or colour

1
2
3 spectral density array were used for the determination of anaesthetic depth.¹⁶ It has been shown that
4 during emergence, volatile anaesthetics induce higher power in frequencies above 15 Hz compared to
5 propofol resulting in higher BIS indices for this drug group.³⁸ Specific index values do not always
6 correlate with the same clinical state of consciousness. We therefore plan to further compare colour
7 spectral density arrays between the groups.
8
9
10
11
12

13
14
15 The use of volatile anaesthetics has been criticized in recent years due to their environmental effects.^{39,40}
16 We are aware that a discontinuation of desflurane has been proposed recently.⁴¹ These recommendations
17 are often based on calculations of the global warming potential of 100 years (GWP₁₀₀), which should be
18 used for gases with atmospheric lifetimes of at least 100 years.⁴² However, since the atmospheric lifetime
19 of desflurane is approximately 14 years, the GWP₁₀₀ formula is inadequate, which often leads to
20 overestimation of its global warming potential.^{42–44} Furthermore, propofol leads to CO₂ emissions and
21 water pollution, which has significant deleterious effects on global warming, which are often
22 underestimated.^{42,43,45} Therefore, it is of utmost importance to provide evidence on patient outcomes
23 before decisions with wide clinical implications will be made. The discontinuation of desflurane and the
24 choice of general anaesthetic in routine care should not be based solely on environmental reasons but
25 also should be supported by their clinical impact and evidence-based results.
26
27
28
29
30
31
32
33
34
35
36
37

38
39
40 This trial will have some limitations. Firstly, due to the different methods of administration and because
41 this is a large, multi-centre, pragmatic trial, blinding of the attending anaesthetists will not be suitable.
42 However, to provide equal depth of anaesthesia, dosage of anaesthetics will be standardized for all
43 patients with an aim of BIS values 50±10. Furthermore, DSA will be further analysed and compared
44 between the groups. To further limit possible bias, all postoperative outcomes will only be assessed by
45 study personnel blinded toward the randomly assigned group. Secondly, we will only include patients
46 planned for major noncardiac surgery. Furthermore, we will only include patients ≥ 65 years of age,
47 since the incidence of postoperative delirium is highest in this patient population.² Thus, the
48 generalisability for emergency surgery, cardiac surgery, and younger patients will be limited. Lastly,
49 some patients might be discharged from the hospital before the fifth postoperative day, limiting the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 delirium assessments. However, based on the current clinical standard of care, patients with delirium
4 are unlikely to be discharged from hospital. Thus, the number of patients with delirium missed in our
5 outcome assessment should be minimal.
6
7
8
9
10

11 In summary, the RAPID-II trial will be a multi-centre, observer-blinded, prospective, randomised
12 clinical trial that is adequately powered to evaluate the effects of desflurane versus sevoflurane versus
13 propofol for maintenance of anaesthesia on the incidence of postoperative delirium in older adults
14 undergoing moderate- to high-risk major noncardiac surgery. The results of this trial might therefore
15 provide evidence regarding the effects of anaesthetics on neurologic outcomes and more importantly
16 will give clinicians guidance for the choice of general anaesthetics in highly vulnerable patients.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial Status

Actual protocol: Version 5.0, March 5, 2024. Patient recruitment started in September 2023.

Funding Statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The authors have no conflicts of interest.

Authors' contributions

AT, CR, EF, BK, BS: conceptualisation and study design; AT, CR, EF, AG: first draft of the manuscript; CE, KH, NA, NH, BH, OZ: data collection; MF, AG: data management; AG: statistical analysis; AT, EF, BK, BS, CE, KH, NA, NH, BH, OZ, MF, AG, CR: editing and critical review of the manuscript; All authors read and approved the final manuscript.

References

- 1
2
3
4
5. Humeidan ML, Reyes JPC, Mavarez-Martinez A, et al. Effect of Cognitive Prehabilitation on
6 the Incidence of Postoperative Delirium among Older Adults Undergoing Major Noncardiac
7 Surgery: The Neurobics Randomized Clinical Trial. *JAMA Surg.* 2021;156(2):148-156.
8
9 doi:10.1001/jamasurg.2020.4371
10
11
12
13
14
15
16. Li GH, Zhao L, Lu Y, et al. Development and validation of a risk score for predicting
17 postoperative delirium after major abdominal surgery by incorporating preoperative risk factors
18 and surgical Apgar score. *J Clin Anesth.* 2021;75(July):110408.
19
20 doi:10.1016/j.jclinane.2021.110408
21
22
23
24
25
26. Mrkobrada M, Chan MTV, Cowan D, et al. Perioperative covert stroke in patients undergoing
27 non-cardiac surgery (NeuroVISION): a prospective cohort study. *The Lancet.*
28 2019;394(10203):1022-1029. doi:10.1016/S0140-6736(19)31795-7
29
30
31
32
33
34
35. Daiello LA, Racine AM, Yun Gou R, et al. Postoperative Delirium and Postoperative
36 Cognitive Dysfunction: Overlap and Divergence. *Anesthesiology.* 2019;131(3):477-491.
37
38 doi:10.1097/ALN.0000000000002729
39
40
41
42
43. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. *The Lancet.*
44 2014;383(9920):911-922. doi:10.1016/S0140-6736(13)60688-1
45
46
47
48
49
50. Rudolph JL, Marcantonio ER. Postoperative Delirium: Acute change with long-term
51 implications. *Anesth Analg.* 2011;112(5):1202-1211. doi:10.1213/ANE.0b013e3182147f6d
52
53
54
55
56. Gleason LJ, Schmitt EM, Kosar CM, et al. Effect of delirium and other major complications on
57 outcomes after elective surgery in older adults. *JAMA Surg.* 2015;150(12):1134-1140.
58
59 doi:10.1001/jamasurg.2015.2606
60

- 1
2
3
4
5 8. Gou RY, Hshieh TT, Marcantonio ER, et al. One-Year Medicare Costs Associated with
6 Delirium in Older Patients Undergoing Major Elective Surgery. *JAMA Surg.* 2021;156(5):430-
7 442. doi:10.1001/jamasurg.2020.7260
8
9
10
11
12
13 9. Goldberg TE, Chen C, Wang Y, et al. Association of delirium with long-term cognitive
14 decline: A meta-analysis. *JAMA Neurol.* 2020;77(11):1373-1381.
15 doi:10.1001/jamaneurol.2020.2273
16
17
18
19
20
21
22 10. Mohanty S, Rosenthal RA, Russell MM, Neuman MD, Ko CY, Esnaola NF. Optimal
23 Perioperative Management of the Geriatric Patient: A Best Practices Guideline from the
24 American College of Surgeons NSQIP and the American Geriatrics Society. *J Am Coll Surg.*
25 2016;222(5):930-947. doi:10.1016/j.jamcollsurg.2015.12.026
26
27
28
29
30
31
32 11. Robinson TN, Raeburn CD, Tran Z V., Brenner LA, Moss M. Motor subtypes of postoperative
33 delirium in older adults. *Archives of Surgery.* 2011;146(3):295-300.
34 doi:10.1001/archsurg.2011.14
35
36
37
38
39
40
41 12. Kunicki ZJ, Ngo LH, Marcantonio ER, et al. Six-Year Cognitive Trajectory in Older Adults
42 Following Major Surgery and Delirium. *JAMA Intern Med.* 2023;183(5):442-450.
43 doi:10.1001/jamainternmed.2023.0144
44
45
46
47
48
49
50 13. Mei X, Zheng HL, Li C, et al. The Effects of Propofol and Sevoflurane on Postoperative
51 Delirium in Older Patients: A Randomized Clinical Trial Study. *Journal of Alzheimer's
52 Disease.* 2020;76(4):1627-1636. doi:10.3233/JAD-200322
53
54
55
56
57
58
59
60

- 1
2
3 14. Saller T, Hubig L, Seibold H, et al. Association between post-operative delirium and use of
4 volatile anesthetics in the elderly: A real-world big data approach. *J Clin Anesth.* 2022;83.
5 doi:10.1016/j.jclinane.2022.110957
6
7
8
9
10 15. Jiang JL, Zhang L, He LL, et al. Volatile Versus Total Intravenous Anesthesia on Postoperative
11 Delirium in Adult Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial.
12 *Anesth Analg.* 2023;136(1):60-69. doi:10.1213/ANE.0000000000006257
13
14
15
16
17
18
19 16. Cao SJ, Zhang Y, Zhang YX, et al. Delirium in older patients given propofol or sevoflurane
20 anaesthesia for major cancer surgery: a multicentre randomised trial. *Br J Anaesth.*
21 2023;131(2):253-265. doi:10.1016/j.bja.2023.04.024
22
23
24
25
26
27
28 17. Iannuzzi E, Iannuzzi M, Viola G, Cerulli A, Cirillo V, Chiefari M. Desflurane and sevoflurane
29 in elderly patients during general anesthesia: a double blind comparison. *Minerva Anestesiol.*
30 2005;71(4):147-155. http://www.ncbi.nlm.nih.gov/pubmed/15756155
31
32
33
34
35
36
37 18. Wang C, Li L, Xu H, Lv H, Zhang H. Effect of desflurane-remifentanil or sevoflurane-
38 remifentanil on early recovery in elderly patients: A meta-analysis of randomized controlled
39 trials. *Pharmazie.* 2019;74(4):201-205. doi:10.1691/ph.2019.8935
40
41
42
43
44
45 19. Yu H, Zhang L, Ma Y, Yu H. Early postoperative recovery in operating room after desflurane
46 anesthesia combined with Bispectral index (BIS) monitoring and warming in lengthy
47 abdominal surgery: A randomized controlled study. *BMC Anesthesiol.* 2018;18(1):1-7.
48 doi:10.1186/s12871-018-0577-6
49
50
51
52
53
54
55
56 20. Heavner JE, Kaye AD, Lin BK, King T. Recovery of elderly patients from two or more hours
57 of desflurane or sevoflurane anaesthesia. *Br J Anaesth.* 2003;91(4):502-506.
58 doi:10.1093/bja/aeg221
59
60


- 1
2
3
4
5 21. De Oliveira GS, Fitzgerald PC, Ahmad S, Jay Marcus R, McCarthy RJ. Desflurane/fentanyl
6 compared with sevoflurane/fentanyl on awakening and quality of recovery in outpatient
7 surgery using a Laryngeal Mask Airway: A randomized, double-blinded controlled trial. *J Clin*
8 *Anesth.* 2013;25(8):651-658. doi:10.1016/j.jclinane.2013.07.006
9
10
11
12
13
14
15
16 22. Taschner A, Fleischmann E, Horvath K, et al. Desflurane versus sevoflurane anesthesia and
17 postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery
18 – A prospective, randomized, observer-blinded, clinical trial. *J Clin Anesth.* 2024;98:111576.
19
20 doi:10.1016/j.jclinane.2024.111576
21
22
23
24
25
26 23. Hamadnalla H, Sessler DI, Troianos CA, et al. Optimal interval and duration of CAM-ICU
27 assessments for delirium detection after cardiac surgery. *J Clin Anesth.*
28
29 2021;71(March):110233. doi:10.1016/j.jclinane.2021.110233
30
31
32
33
34
35 24. Marcantonio ER, Ngo LH, Connor MO, et al. 3D-CAM: Derivation and Validation of a 3-
36 Minute Diagnostic Interview for CAM-defined Delirium. *Ann Intern Med.* 2014;161(8):554-
37 561. doi:10.7326/M14-0865.3D-CAM
38
39
40
41
42
43 25. Evered LA, Silbert BS. Postoperative cognitive dysfunction and noncardiac surgery. *Anesth*
44 *Analg.* 2018;127(2):496-505. doi:10.1213/ANE.0000000000003514
45
46
47
48
49
50 26. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction
51 in the elderly: ISPOCD1 study. *Lancet.* 1998;351(9106):857-861. doi:10.1016/S0140-
52 6736(97)07382-0
53
54
55
56
57
58 27. Krishnan K, Rossetti H, Hynan LS, et al. Changes in Montreal Cognitive Assessment Scores
59 Over Time. *Assessment.* 2017;24(6):772-777. doi:10.1177/1073191116654217
60

- 1
2
3
4
5 28. Tan HH, Xu J, Teoh HL, et al. Decline in changing montreal cognitive assessment (MoCA)
6 scores is associated withpost-stroke cognitive decline determined by a formal
7 neuropsychological evaluation. *PLoS One*. 2017;12(3). doi:10.1371/journal.pone.0173291
8
9
10
11
12
13
14 29. Pendlebury ST, Welch SJ V, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone
15 assessment of cognition after TIA and stroke : TICSm and telephone MoCA vs face-to-face
16 MoCA and neuropsychological battery. *Stroke*. 2013;44(1):227-229.
17
18 doi:10.1161/STROKEAHA.112.673384.Telphone
19
20
21
22
23
24 30. Zietemann V, Kopczak A, Müller C, Wollenweber FA, Dichgans M. Validation of the
25 telephone interview of cognitive status and telephone montreal cognitive assessment against
26 detailed cognitive testing and clinical diagnosis of mild cognitive impairment after stroke.
27
28 *Stroke*. 2017;48(11):2952-2957. doi:10.1161/STROKEAHA.117.017519
29
30
31
32
33
34
35 31. Takeuchi M, Takeuchi H, Fujisawa D, et al. Incidence and risk factors of postoperative
36 delirium in patients with esophageal cancer. *Ann Surg Oncol*. 2012;19(12):3963-3970.
37
38 doi:10.1245/s10434-012-2432-1
39
40
41
42
43 32. Robinson TN, Raeburn CD, Tran Z V., Angles EM, Brenner LA, Moss M. Postoperative
44 delirium in the elderly: Risk factors and outcomes. *Ann Surg*. 2009;249(1):173-178.
45
46 doi:10.1097/SLA.0b013e31818e4776
47
48
49
50
51
52 33. Wildes TS, Mickle AM, Abdallah A Ben, et al. Effect of electroencephalography-guided
53 anesthetic administration on postoperative delirium among older adults undergoing major
54 surgery the engages randomized clinical trial. *JAMA - Journal of the American Medical
55 Association*. 2019;321(5):473-483. doi:10.1001/jama.2018.22005
56
57
58
59
60

- 1
2
3 34. Wissing H, Kuhn I, Rietbrock S, Fuhr U. *Pharmacokinetics of Inhaled Anaesthetics in a*
4 *Clinical Setting: Comparison of Desflurane, Isoflurane and Sevoflurane* †. Vol 84.; 2000.
5
6
7
8
9 35. Lockwood G. Theoretical context-sensitive elimination times for inhalation anaesthetics. *Br J*
10 *Anaesth.* 2010;104(5):648-655. doi:10.1093/bja/aeq051
11
12
13
14
15 36. Bailey JM. Context-Sensitive Half-Times and Other Decrement Times of Inhaled Anesthetics.
16 *Anesth Analg.* 1997;85:681-686.
17
18
19
20
21
22 37. Tachibana S, Hayase T, Osuda M, Kazuma S, Yamakage M. Recovery of postoperative
23 cognitive function in elderly patients after a long duration of desflurane anesthesia: a pilot
24 study. *J Anesth.* 2015;29(4):627-630. doi:10.1007/s00540-015-1979-y
25
26
27
28
29
30 38. Lipp M, Schneider G, Kreuzer M, Pilge S. Substance-dependent EEG during recovery from
31 anesthesia and optimization of monitoring. *J Clin Monit Comput.* 2024;38(3):603-612.
32
33
34
35
36
37
38 39. White SM, Shelton CL. Abandoning inhalational anaesthesia. *Anaesthesia.* 2020;75(4):451-
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 40. Ryan SM, Nielsen CJ. Global warming potential of inhaled anesthetics: Application to clinical
use. *Anesth Analg.* 2010;111(1):92-98. doi:10.1213/ANE.0b013e3181e058d7
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 41. Van Norman GA, Jackson S. The anesthesiologist and global climate change: an ethical
obligation to act. *Curr Opin Anaesthesiol.* 2020;33(4):577-583.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 doi:10.1097/ACO.0000000000000887

- 1
2
3 42. Slingo JM, Slingo ME. The science of climate change and the effect of anaesthetic gas
5 emissions. *Anaesthesia*. Published online 2024. doi:10.1111/anae.16189
6
7
8
9 43. Tapley P, Patel M, Slingo M. Abandoning inhalational anaesthesia. *Anaesthesia*.
10 2020;75(9):1257-1258. doi:10.1111/anae.15142
11
12
13
14
15 44. Pierrehumbert RT. Short-lived climate pollution. *Annu Rev Earth Planet Sci*. 2014;42:341-379.
16
17 doi:10.1146/annurev-earth-060313-054843
18
19
20
21
22 45. Kostrubiak M, Vatovec CM, Dupigny-Giroux LA, et al. Water Pollution and Environmental
23 Concerns in Anesthesiology. *J Med Syst*. 2020;44(9):169. doi:10.1007/s10916-020-01634-
24
25
26 2/Published
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study procedure



BIS, bispectral index; ICU, intensive care unit.

Supplementary Online Content

eAppendix 1. List of investigators RAPID II Trial

eAppendix 2. Definition of moderate- to high-risk major noncardiac surgery

This supplementary material has been provided by the authors to give readers additional information about their work.

eAppendix 1. List of investigators RAPID II Trial

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Medical University of Vienna: Nikolas Adamowitsch; David Emler; Edith Fleischmann; Melanie Fraunschiel; Alexandra Graf; Nicole Hantakova; Beatrix Hochreiter; Kira Margarete Hörl; Katharina Horvath; Barbara Kabon; Helena Langthaler; Magdalena List; Christian Reiterer; Barbara Rossi; Simon Schallmeiner; Mathias Stiefsohn; Alexander Taschner; Giulia Zanvettor; Florian Wolfgang Zenz; Oliver Zotti;
2. Medical University of Innsbruck: Christine Eckhardt; Iris Emshoff; Christoph Geiger; Nicole Innerhofer; Mario Kofler; Sasa Rajsic; Beatrix Reyer; Barbara Sinner; Susanne Trübsbach; Melanie Widmann;

eAppendix 2. Definition of moderate- to high-risk major noncardiac surgery

We defined the following surgeries to meet the criteria for moderate- to high-risk major noncardiac surgery:

- Major general surgery: complex visceral resection, partial or total colectomy, gastrectomy, partial liver resection, pancreas resection, oesophageal resection, anterior rectal resection, retroperitoneal tumour resection, small bowel resection
- Major urologic surgery: prostatectomy, cystectomy, nephrectomy, retroperitoneal tumour resection, major open lymphadenectomy
- Major gynaecologic surgery: retroperitoneal tumour resection, exenteration, cytoreduction surgery, open hysterectomy
- Major orthopaedic surgery: total hip replacement, partial hip replacement, total knee replacement

Table 1: Inclusion and Exclusion Criteria*Inclusion criteria (1-3)*

1. Provided written informed consent
2. ≥ 65 years of age
3. Scheduled for elective major non-cardiac surgery with estimated time of surgery ≥ 2 hours

Exclusion criteria (1-9)

1. Patients undergoing emergency surgery
2. $BMI > 45\text{kg.m}^{-2}$
3. History of diagnosed dementia
4. Language, vision, or hearing impairments that may compromise cognitive assessments
5. History of malignant hyperthermia
6. History of structural muscle disease
7. History of organ transplantation (kidney, liver, lung, heart)
8. Patients undergoing hyperthermic intraperitoneal chemotherapy surgery
9. ICU patients undergoing surgery

BMI, body mass index; ICU, intensive care unit.

Table 2: Outcome assessments

Outcome	Measurements	Timepoint
<i>Primary Outcome</i>		
Postoperative delirium	3D-CAM/CAM-ICU	Evening on the day of surgery and morning and evening of the first five postoperative days
<i>Secondary Outcomes</i>		
Delayed neurocognitive recovery	DSST, TMT Part A, TMT Part B	Preoperative, postoperative day 5
Need of supplemental oxygen	Litres.minute ⁻¹	During PACU/ICU stay
Length of stay in ICU	Number of days at ICU	During ICU stay
Early PONV	Patient assessment of PONV episode	First two hours after surgery
Late PONV	Patient assessment of PONV episode	Evening on the day of surgery and morning and evening of the first five postoperative days
Intraoperative hypotension	Intraoperative mean arterial pressure + cumulative catecholamine administration	Intraoperative
Death within 5 days		First five postoperative days
<i>Exploratory Outcomes</i>		
Days at home up to 30 days after surgery (DAH ₃₀)	Phone Follow-Up, patient records	30 days after surgery
Long-term neurocognitive disorder	MoCA test via phone Follow-Up	Preoperative, 1 year after surgery
AUC of inflammatory biomarkers	CRP, IL-6, PCT	Preoperative, within two hours after surgery, postoperative day 2
AUC of cardiac biomarkers	Troponin T, NT-proBNP, Copeptin	Preoperative, within two hours after surgery, postoperative day 2
AUC of neuronal injury biomarkers	S100-B, NSE	Preoperative, within two hours after surgery, postoperative day 2
One-year all-cause mortality		One year after surgery
<i>Sub-Study Outcomes</i>		
Advanced Neuro-Biomarkers	NfL, GFAP	Preoperative, postoperative day 3

1
2
3 CAM, confusion assessment method; ICU, intensive care unit; dNR, delayed neurocognitive recovery; DSST, digit symbol
4 substitution test; TMT, trail making test; PACU, post-anaesthesia care unit; PONV, postoperative nausea and vomiting;
5 DAH₃₀, number of days at home in the first month after surgery; NCD, neurocognitive disorder; MoCA, Montreal Cognitive
6 Assessment; AUC, area under the curve; CRP, C-reactive protein; IL-6, Interleukin-6; PCT, Procalcitonin; NT-proBNP, N-
7 terminal pro-brain-natriuretic peptide; NSE, neuron-specific enolase; NfL, neurofilament light chain; GFAP, glial fibrillary
8 acidic protein.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

The effect of desflurane, sevoflurane, or propofol on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery: study protocol for a prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2024-092611.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Oct-2024
Complete List of Authors:	Taschner, Alexander; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Fleischmann, Edith; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Kabon, Barbara; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Sinner, Barbara; Medical University Innsbruck, Department of Anaesthesia and Intensive Care Eckhardt, Christine; Medical University Innsbruck, Department of Anaesthesia and Intensive Care Horvath, Katharina; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Adamowitsch, Nikolas; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Hantakova, Nicole; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Hochreiter, Beatrix; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Zotti, Oliver; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Fraunschiel, Melanie; Medical University of Vienna, IT Services and strategic information management Graf, Alexandra; Medical University of Vienna, Institute of Medical Statistics, Centre for Medical Data Science Reiterer, Christian; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine

Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Delirium, Adult anaesthesia < ANAESTHETICS, ANAESTHETICS, Randomized Controlled Trial

SCHOLARONE™
Manuscripts

1
2
3
4
5 **The effect of desflurane, sevoflurane, or propofol on the incidence of postoperative delirium in**
6 **older adults undergoing moderate- to high-risk major noncardiac surgery: study protocol for a**
7
8 **prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)**

9
10
11
12
13
14
15
16
17 Alexander Taschner¹; Edith Fleischmann¹; Barbara Kabon¹; Barbara Sinner²; Christine Eckhardt²;
18 Katharina Horvath¹; Nikolas Adamowitsch¹; Nicole Hantakova¹; Beatrix Hochreiter¹; Oliver Zotti¹;
19
20 Melanie Fraunschiel³; Alexandra Graf⁴; Christian Reiterer^{1*} for the RAPID-II investigator group
21
22
23 (eAppendix 1 in the Online Supplement)

24
25
26
27
28
29
30 ¹ Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain
31 Medicine, Division of General Anaesthesia and Intensive Care Medicine, 1090 Vienna, Austria

32
33
34 ² Department of Anaesthesia and Intensive Care, Medical University Innsbruck, 6020 Innsbruck,
35 Austria

36
37 ³ IT Services and strategic information management, Medical University of Vienna, 1090 Vienna,
38 Austria

39
40 ⁴ Institute of Medical Statistics, Centre for Medical Data Science, Medical University of Vienna, 1090
41 Vienna, Austria

42
43 * Correspondence to:

44
45 Prof. Christian Reiterer, M.D., Ph.D.

46
47 Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of
48 Vienna; Spitalgasse 23, 1090 Vienna, Austria.

49
50 christian.reiterer@meduniwien.ac.at; Phone: 0043 1 40400 20760

51
52 Word count: 4309 words

Abstract

Introduction: The effect of different anaesthetics on the incidence of postoperative delirium is still not entirely clear. Therefore, we will evaluate the effect of desflurane versus sevoflurane versus propofol for maintenance of anaesthesia on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery. We will further compare the incidences of delayed neurocognitive recovery, long-term postoperative neurocognitive disorder, postoperative nausea and vomiting between the groups.

Methods and analysis: In this multi-centre, prospective, observer-blinded, randomised controlled clinical trial we will include 1332 patients ≥ 65 years of age undergoing moderate- to high-risk major noncardiac surgery lasting at least two hours. Patients will be randomly 1:1:1 assigned to receive desflurane, sevoflurane or propofol for anaesthesia. Maintenance of anaesthesia will be performed in a goal-directed manner using processed electroencephalography with an intraoperative goal of bispectral index 40 to 60. Our primary outcome will be the incidence of postoperative delirium within the first five postoperative days. Postoperative delirium will be assessed using the 3D-Confusion Assessment Method (3D-CAM) or CAM-ICU in the morning and evening of the first five postoperative days by blinded study personnel. The primary outcome, the incidence of postoperative delirium, will be compared between the three study groups using a Chi-Square-test. Furthermore, a logistic regression model for the incidence of postoperative delirium will be performed accounting for randomised group as well as other pre-defined confounding factors.

Ethics and dissemination: This clinical trial has been approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria. The results of this trial will be published in a peer-reviewed journal.

Trial registration:

ClinicalTrials.gov NCT05990790;

<https://clinicaltrials.gov/study/NCT05990790?term=NCT05990790&rank=1>

1
2
3 **Strengths and limitations of this study:**
4

- 5 - This will be a multi-centre prospective trial powered to detect a 10% absolute risk reduction in
6 postoperative delirium between desflurane, sevoflurane, and propofol.
7
8 - This trial will achieve good internal validity due to randomisation and blinding of outcome
9 assessors as well as high external validity due to the large sample size and the inclusion of many
10 types of noncardiac surgery.
11
12 - Postoperative delirium will be assessed in the morning and evening for the initial five
13 postoperative days according to the current recommendations.
14
15 - Due to the different methods of administration of the three anaesthetics, blinding of the
16 attending anaesthetists will not be performed.
- 17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Postoperative delirium is a major complication after cardiac and noncardiac surgery and occurs more often in older adults.^{1–3} Based on previous observational studies, the incidence of postoperative delirium in older adults is between 20 and 45%.^{4–6} Delirium is associated with prolonged stay in intensive care units (ICU) and hospitalisation, leading to higher hospitalisation costs, which are as high as costs caused by cardiovascular complications.^{4,5,7,8} More importantly, postoperative delirium is associated with accelerated long-term neurocognitive decline and dementia and further increases morbidity and mortality.^{4,5,9–12} In this context, the American College of Surgeons and the American Society of Anesthesiologists have identified the prevention of postoperative delirium as a public health priority.^{8,10} Nevertheless, a clear consensus on perioperative anaesthesiologic management of older adults undergoing major noncardiac surgery with the specific goal of preventing postoperative delirium has not been established yet.¹⁰

Some previous studies evaluated the effects of volatile versus intravenous anaesthesia on the incidence of postoperative delirium.^{13–16} However, these studies mostly compared sevoflurane versus propofol anaesthesia and showed conflicting results.^{13–16} The most recent and largest randomised trial showed a significantly lower incidence of postoperative delirium after propofol-anaesthesia as compared to sevoflurane-anaesthesia.¹⁶ However, so far data regarding the effects of desflurane as compared to sevoflurane and propofol on the incidence of postoperative delirium is scarce. While it has been shown previously that desflurane anaesthesia leads to significantly faster immediate postoperative recovery as compared to sevoflurane,^{17–21} we could not observe in one of our previous studies a significant difference immediate postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery.²² Nevertheless, the effect of desflurane versus sevoflurane versus propofol on the incidence of postoperative delirium in older adults undergoing major noncardiac surgery is still unclear.

Therefore, we will test our primary hypothesis that anaesthesia with desflurane will be associated with a significantly lower incidence of postoperative delirium within the first five postoperative days as compared to anaesthesia with sevoflurane or anaesthesia with propofol in older adults undergoing

1
2
3 moderate- to high-risk major noncardiac surgery lasting at least two hours. We will further test the
4 secondary hypotheses that anaesthesia with desflurane will be associated with significantly lower
5 incidences of delayed neurocognitive recovery and long-term neurocognitive disorder as compared to
6 anaesthesia with sevoflurane or anaesthesia with propofol.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods and Analysis

Trial Design

We will conduct the RAPID-II trial, a multi-centre, observer-blinded, prospective, randomised, three-arm parallel arm clinical trial at the Medical University of Vienna and the Medical University Innsbruck. All members of the RAPID-II investigator group are listed in Online Supplement 1. We will include 1332 patients ≥ 65 years of age undergoing moderate- to high-risk major noncardiac surgery. The trial was approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria on the 19th of June 2023 (CTIS Reference number: 2023-503717-30-00). We started patient enrolment on the 3rd of September 2023.

Study population

The inclusion and exclusion criteria are presented in Table 1. Study personnel will screen the surgical schedule the day before surgery and check for eligibility. Definitions of surgeries, which will be included are listed in eAppendix 2 of the Online Supplement. They will further approach eligible patients to obtain informed consent before surgery. Previous experience showed that 6-8 patients will be eligible per week. Therefore, we assume a period of 3-4.5 years to complete patient recruitment for this study.

Table 1: Inclusion and Exclusion Criteria

Inclusion criteria (1-3)

1. Provided written informed consent
2. ≥ 65 years of age
3. Scheduled for elective major non-cardiac surgery with estimated time of surgery ≥ 2 hours

Exclusion criteria (1-9)

1. Patients undergoing emergency surgery
2. $BMI > 45\text{kg.m}^{-2}$
3. History of diagnosed dementia
4. Language, vision, or hearing impairments that may compromise cognitive assessments
5. History of malignant hyperthermia
6. History of structural muscle disease
7. History of organ transplantation (kidney, liver, lung, heart)
8. Patients undergoing hyperthermic intraperitoneal chemotherapy surgery
9. ICU patients undergoing surgery

BMI, body mass index; ICU, intensive care unit.

5 6 *Data management*

7
8 Electronic data will be recorded in the data management system “ClinCase”, Version 2.7.0.12 hosted by
9
10 IT Services & strategic information management of the Medical University of Vienna, Vienna, Austria.
11
12

13 14 *Randomisation and blinding*

15
16 We will randomise patients within one hour before surgery. We will use the online randomisation
17 programme “Randomizer” (Randomizer, Medical University of Graz, Graz, Austria:
18 <https://www.meduniwien.ac.at/randomizer/web/login.php>) provided by the IT Services & strategic
19 information management Department of the Medical University of Vienna, 1090 Vienna, Austria.
20
21 Randomisation will be performed with permuted blocks stratified by study centre, sex, and age (65-
22 79 years, ≥80 years). Randomisation will only be performed by registered personnel, who are not
23 involved in postoperative outcome assessments. The attending anaesthetists will be informed about the
24 randomly assigned group and will not be involved in postoperative outcome assessments. Only study
25 personnel responsible for postoperative outcome assessments will be blinded regarding the randomly
26 assigned group. Patients will be randomised 1:1:1 to the following three groups:
27
28

29
30 **Desflurane group:** after induction of anaesthesia, anaesthesia will be maintained with goal-directed
31 administration of desflurane with an intraoperative goal of bispectral index (BIS) 40 to 60.
32
33

34
35 **Sevoflurane group:** after induction of anaesthesia, anaesthesia will be maintained with goal-directed
36 administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 40 to 60.
37
38

39
40 **Propofol group:** after induction of anaesthesia, anaesthesia will be maintained with a goal-directed
41 continuous infusion of propofol with an intraoperative goal of bispectral index (BIS) 40 to 60.
42
43

44 45 *Anaesthesia protocol*

46
47 All patients will receive an ECG, blood pressure and peripheral oxygen saturation monitoring. An
48 arterial line and/or central venous line will be placed and monitored at the discretion of the attending
49 anaesthetist according to local clinical standard of care.
50
51

1
2
3 After endotracheal intubation, anaesthesia will be maintained using desflurane or sevoflurane in a mixed
4 oxygen carrier gas or continuous propofol infusion according to the allocated randomised group. We
5 will use the first 10 minutes after intubation to set anaesthesia to the target BIS value. Desflurane,
6 sevoflurane and propofol respectively will be titrated and adjusted using processed
7 electroencephalography for a target BIS of 40 to 60 throughout surgery.
8
9

10 Fentanyl and remifentanil, respectively, will be administered at the discretion of the attending
11 anaesthetist. We will give additional muscle relaxation to maintain 1-2 mechanical twitches in response
12 to supra-maximal stimulation (Train-of-four stimulation, target <75%). For mechanical ventilation, we
13 will maintain an inspiratory FiO_2 between 0.3 and 0.5 to achieve a SpO_2 of at least 93% or pO_2 of
14 >80mmHg. Tidal volumes will be set between 6 and 8mL lean body weight to maintain end-tidal CO_2
15 within 35-40mmHg. Positive end-expiratory pressure will be set at 5mmHg or higher according to the
16 patients' requirements. Intraoperative PONV prophylaxis will be administered at the discretion of the
17 attending anaesthetist. We will actively warm patients with convective warming to maintain
18 perioperative normothermia. Intraoperative mean arterial pressure will be held at a minimum of
19 65mmHg. Intraoperative fluid and vasopressor management will be performed at the discretion of the
20 attending anaesthetist according to local clinical standard of care. We will maintain a haemoglobin of at
21 least 8 g.dL^{-1} . Anaesthesiologic adjuvants, e.g. esketamine, clonidine, atropine, dexmedetomidine,
22 midazolam, and scopolamine should be avoided. The postoperative management of medication will be
23 done according to the attending physicians.

24 At the end of surgery, we will stop the administration of desflurane, sevoflurane, and propofol
25 respectively. In the case of planned intubated transfer to intensive care units (ICU) after surgery,
26 desflurane or sevoflurane will be stopped and propofol administration will be started (Figure 1).

51 Outcomes

52 Our primary outcome will be the incidence of postoperative delirium within the first five postoperative
53 days between the desflurane, sevoflurane, and propofol groups.

54 Our secondary outcomes will include the incidence of delayed neurocognitive recovery, postoperative
55 need of supplemental oxygen, length of stay in the ICU, incidence of postoperative nausea and vomiting

(PONV) in the early and late postoperative periods, intraoperative hypotension, and death within the first five postoperative days.

Our exploratory outcomes will include the number of days at home up to 30 days after surgery, long-term postoperative neurocognitive disorder one year after surgery, and postoperative area under the curve of plasma concentrations of inflammatory biomarkers (C-reactive protein (CRP), Interleukin-6 (IL-6), Procalcitonin (PCT)), cardiac biomarkers (Troponin T, N-terminal pro-brain natriuretic peptide (NT-proBNP), Copeptin), and neuronal injury biomarkers (S100-B, Neuron-specific enolase (NSE)).

Study specific blood samples will be drawn shortly before induction of anaesthesia, within two hours after surgery and on the second postoperative day. Furthermore, we will assess one-year all-cause mortality one year after surgery in all patients.

In a sub-study, we will compare differences between preoperative and postoperative concentrations of advanced neuro-biomarkers including neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) between the groups.

A detailed description of primary, secondary, exploratory, and sub-study specific outcomes and their assessments is shown in Table 2.

Table 2: Outcome assessments

Outcome	Measurements	Timepoint
<i>Primary Outcome</i>		
Postoperative delirium	3D-CAM/CAM-ICU	Evening on the day of surgery and morning and evening of the first five postoperative days
<i>Secondary Outcomes</i>		
Delayed neurocognitive recovery	DSST, TMT Part A, TMT Part B	Preoperative, postoperative day 5
Need of supplemental oxygen	Litres.minute ⁻¹	During PACU/ICU stay
Length of stay in ICU	Number of days at ICU	During ICU stay
Early PONV	Patient assessment of PONV episode	First two hours after surgery
Late PONV	Patient assessment of PONV episode	Evening on the day of surgery and morning and

evening of the first five
postoperative days

Intraoperative hypotension	Intraoperative mean arterial pressure + cumulative catecholamine administration	Intraoperative
Death within 5 days		First five postoperative days

Exploratory Outcomes

Days at home up to 30 days after surgery (DAH ₃₀)	Phone Follow-Up, patient records	30 days after surgery
Long-term neurocognitive disorder	MoCA test via phone Follow-Up	Preoperative, 1 year after surgery
AUC of inflammatory biomarkers	CRP, IL-6, PCT	Preoperative, within two hours after surgery, postoperative day 2
AUC of cardiac biomarkers	Troponin T, NT-proBNP, Copeptin	Preoperative, within two hours after surgery, postoperative day 2
AUC of neuronal injury biomarkers	S100-B, NSE	Preoperative, within two hours after surgery, postoperative day 2
One-year all-cause mortality		One year after surgery

Sub-Study Outcomes

Advanced Neuro-Biomarkers	NfL, GFAP	Preoperative, postoperative day 3
---------------------------	-----------	--------------------------------------

CAM, confusion assessment method; ICU, intensive care unit; dNR, delayed neurocognitive recovery; DSST, digit symbol substitution test; TMT, trail making test; PACU, post-anaesthesia care unit; PONV, postoperative nausea and vomiting; DAH₃₀, number of days at home in the first month after surgery; NCD, neurocognitive disorder; MoCA, Montreal Cognitive Assessment; AUC, area under the curve; CRP, C-reactive protein; IL-6, Interleukin-6; PCT, Procalcitonin; NT-proBNP, N-terminal pro-brain-natriuretic peptide; NSE, neuron-specific enolase; NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein.

Measurements

Demographic and morphometric data

Basic data including age, sex, body mass index, and ASA physical status, will be recorded. We will record medical history including comorbidities, long-term medication, and history of tobacco or alcohol use and type of surgery.

Perioperative data

Routine intra- and postoperative anaesthesia specific data will be extracted from our electronic anaesthesia records. Intraoperative data will include arterial blood gas analysis, durations of anaesthesia and surgery, intraoperative fluid management, intraoperative medication, vasopressors, and haemodynamic data.

We will further record inspiratory and expiratory concentrations of the administered volatile anaesthetic and intraoperative amount of propofol. Intraoperative BIS data (BISTM, Medtronic[®], Meerbusch, Germany) including BIS values and density spectral array (DSA) will be recorded and extracted directly from the BIS monitor.

Postoperative pain will be recorded based on the numeric pain rating scale (NRS) in the PACU, ICU, and on the ward twice daily within the first five postoperative days. We will record the overall amount of piritramide, non-steroidal analgesics, duration of epidural anaesthesia, and the amount of co-analgesics administered at the PACU, ICU, or on the ward within the first five postoperative days.

Outcome measurements

All postoperative outcome assessments will be performed by trained study personnel, who are blinded to the assigned randomised group.

For our primary outcome, we will perform the 3D-confusion assessment method (3D-CAM) evaluations starting on the evening of the day of surgery (6 p.m.–10 p.m.). Following 3D-CAM evaluations will be performed twice daily – in the mornings (5 a.m.–11 a.m.) and evenings (6 p.m.–10 p.m.) for the following five postoperative days if patients are still hospitalised.^{23,24} In patients in the ICU, we will perform CAM-ICU evaluations.^{23,24} Postoperative delirium will be defined as occurrence of at least one positive 3D-CAM or CAM-ICU assessment in the first five postoperative days.

For the assessment of delayed neurocognitive recovery, we will perform digit symbol substitution tests (DSST), trail making test (TMT) part A and part B before surgery and on the fifth postoperative day if the patients are still hospitalised.^{25,26} For the TMT the time until test completion and the number of mistakes will be recorded. If the patients are intubated on the fifth postoperative day, the assessments will be postponed for two days. Delayed neurocognitive recovery will be defined in accordance with the

ISOPOCD-1 study when a patient has a Z-score on two or all tests or the combined Z-score is below -1.96 standard deviation.²⁶

For the assessment of neurocognitive disorder, we will further perform an adapted Montreal Cognitive Assessment (MoCA) test (telephone MoCA) before surgery and one year after surgery.²⁷⁻³⁰ Postoperative neurocognitive disorder will be defined as a decrease of two points or more from baseline values.²⁷⁻³⁰

DSST, TMT, 3D-CAM, CAM-ICU, and MoCA tests will be performed only by trained and blinded study personnel. PONV will be assessed on the evening of the day of surgery and in the morning and evening of the following five days. PONV will be defined as subjective symptoms of nausea and/or occurrence of vomiting at each timepoint. Oxygen supplementation will be recorded by number of litres.minute⁻¹ oxygen administered for SpO₂ ≥93% at PACU or ICU respectively. Furthermore, we will record the intraoperative use of vasopressors. We will record the duration of stay in the ICU in all patients. Phone follow-ups will be performed in all patients 30 days after surgery to determine the number of days at home up to 30 days after surgery and one year after surgery to perform the MoCA tests.

Study specific blood samples will include CRP, IL-6, PCT, Troponin T, NT-proBNP, Copeptin, NSE, S100-B, NfL, and GFAP. All laboratory parameters will be measured at the Department of Laboratory Medicine at the Medical University of Vienna and at the Department of Laboratory Medicine at the Medical University Innsbruck respectively. Blood samples will be treated with standard of care to provide best accuracy of measurement. Study specific blood samples of CRP, IL-6, PCT, Troponin T, NT-proBNP, Copeptin, NSE, and S100-B will be drawn shortly before induction of anaesthesia, within two hours after surgery and on the second postoperative day. Sub-study specific blood samples of NfL and GFAP will be collected shortly before induction of anaesthesia and on the third postoperative day. Sub-study specific blood samples will then be centrifuged and stored.

56 *Statistical analysis*

57 Data analysis

1
2 Baseline characteristics such as age, sex, ASA physical status, history of tobacco use, comorbidities,
3 long-term medication, and type of surgery will first be analysed descriptively. Descriptive statistics will
4 be calculated overall and separately for the three groups. Continuous variables will be summarised using
5 means, standard deviations, median, and interquartile ranges. Categorical data will be summarised using
6 absolute numbers and percentages.
7
8

9 Our primary outcome, the incidence of postoperative delirium, will be described in a descriptive way
10 using absolute numbers and percentages per study group. First, we will compare the incidence of
11 postoperative delirium between the three groups using a Chi-Square-test. Furthermore, a logistic
12 regression model for the incidence of postoperative delirium will be performed accounting for
13 randomised group as well as other confounding factors (e.g. age, BMI, ASA physical status, duration of
14 anaesthesia, additional epidural/regional anaesthesia, history of cerebrovascular disease). All three
15 groups will be analysed together in the logistic regression model and the pairwise comparison will be
16 conducted within the model. Patients, who die within the first five postoperative days will be excluded
17 from the primary analysis of our trial, unless positive delirium assessment were performed before
18 patients' death. As sensitivity analysis, to additionally account for death within 5 days after surgery, a
19 logistic regression model for the probability of the combined endpoint (postoperative delirium or death)
20 will be performed accounting for randomised group and other possible confounding factors.
21 Significance levels for the primary outcome will be used as described in the sample size calculation
22 section to account for the two interim analyses and the pairwise group comparisons to retain an overall
23 level for the type I error of 0.05
24
25

26 All analyses will be conducted on the ITT population, defined as all randomized patients, who received
27 one of the study drugs, even if the patient does not receive the correct treatment, or otherwise does not
28 follow the protocol. In addition to intention to treat analyses also per-protocol analyses will be performed
29 for the primary and secondary parameters. This analysis set comprises all subjects, who received one of
30 the study drugs and did not violate the protocol in a way that might affect the evaluation of the effect of
31 the study drug(s) on the primary objective, i.e., without major protocol violations.
32
33

34 The secondary outcome, the incidence of delayed neurocognitive recovery, will be evaluated between
35 the study groups using a Chi-Square-test. Furthermore, a logistic regression model for the probability of
36

1
2
3 delayed neurocognitive recovery will be performed accounting for randomised group as well as other
4 possible confounding factors.
5
6

7 The secondary outcome, the number of litres of administered supplemental oxygen in PACU or ICU to
8 achieve a $\text{SpO}_2 \geq 93\%$ will be compared between the study groups using Mann-Whitney-U tests.
9
10

11 The secondary outcome, the length of stay in the ICU, will be compared between the groups using a
12 competing risk model for time to discharge from ICU and death as competing event accounting for study
13 group as well as other possible confounding factors.
14
15

16 The secondary outcomes, incidences of PONV in the early and late postoperative period, will be
17 evaluated between the groups using Chi-Square-tests. Furthermore, logistic regression models for the
18 incidences of PONV in the early and late postoperative period will be performed.
19
20

21 The secondary outcome, intraoperative duration of MAP $<65\text{mmHg}$ and the overall intraoperatively
22 administered amount of catecholamines, will be compared between the groups using Mann-Whitney-U
23 tests.
24
25

26 The secondary outcome, death within five days after surgery, will be compared between the groups
27 using a Chi-Square-test. Furthermore, a logistic regression model for the probability of death will be
28 performed.
29
30

31 The exploratory outcome, number of days at home up to 30 days after surgery, will be compared between
32 the groups using Mann-Whitney-U tests. The exploratory outcome, incidence of neurocognitive disorder
33 one year after surgery, will be compared using Chi-Square-tests. As exploratory outcomes, area under
34 the curves of perioperative inflammatory biomarkers, cardiac biomarkers, and neuronal injury
35 biomarkers, will be calculated and compared between the groups using Mann-Whitney-U tests. Lastly,
36 probability of all-cause death within one year after surgery will be presented between the groups using
37 Kaplan-Meier curves. For secondary and exploratory outcomes, a significance level of 0.05 is used.
38
39

40 Sample size calculation

41
42
43
44
45
46
47
48
49
50

51 We estimated the number of patients required for this trial based on previous studies, which showed that
52 the incidence of postoperative delirium in older adults undergoing major abdominal surgery lies between
53 5-50%,^{5,31,32} whereas the largest study reported an incidence of 25%.³³ Using a conservative approach,
54
55
56
57
58
59
60

we assumed the incidence of postoperative delirium at about 25%. A reduction of 10% points was assumed to be clinically relevant (25% versus 15%).

Two interim analyses, one after 1/3 and one after 2/3 of recruitment are pre-planned. To correct for the comparison of the three groups, Bonferroni-correction was applied resulting in a two-sided overall significance level of 0.0167 (0.05/3 for three comparisons). To further correct for the two interim-analyses (three total analyses including final analysis), the Hwang-Shih-DeCani spending function for group sequential designs (with associated parameter -4) was used resulting in a nominal alpha level of 0.001 for the first interim analysis, 0.004 for the second interim analysis, and 0.015 for the final analysis to control the overall significance level of 0.0167 for each of the three group comparisons.

Using a group sequential z-test and assuming an odds ratio of 0.529 (for proportions of 0.25 as compared to 0.15), we calculated a needed sample size of 431 patients per group to achieve a power of 0.9.

We assumed a drop-out rate of 3% (including patients, who die within the first five postoperative days), resulting in a needed sample size of 1332 patients (444 patients per group).

The sample size calculation was performed using NQuery 8.

Data safety monitoring board

The following experienced researchers will comprise the Data Safety Monitoring Board (DSMB): Prof. Dr. Eva Base (Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of Cardiothoracic and Vascular Anaesthesia, Medical University of Vienna, Austria), Prof. Dr. Michael Wolzt (Department of Clinical Pharmacology, Medical University of Vienna, Austria), Prof. Dr. Markus Zeitlinger (Department of Clinical Pharmacology, Medical University of Vienna, Austria), Prof. Dr. Gerd Silberhumer (Department of General Surgery, Medical University of Vienna, Austria).

Patients' safety will be monitored through the data and safety monitoring board. The DSMB will evaluate adverse events (AEs, SAEs, SUSARs, ADR) for the two pre-planned interim analyses. In detail, the DSMB will evaluate adverse events from 444 patients and 888 patients after all data are available. It will be the responsibility of this committee to alert the local ethics committee via letter of any harmful effects in one of the study groups. This committee, along with the local ethics committee will have the

1
2
3 exclusive authority to stop the study either for futility, harm, or clear benefit. Any morbidity potentially
4 related to the study protocol will be reported to the ethics committee.
5
6
7
8
9

10 *Emergency unblinding and termination of the study drug*

11 Attending anaesthesiologists will not be blinded for respective anaesthetic agents. In the case of
12 discontinuation or change of the randomly assigned group, assessments of postoperative outcomes will
13 be continued according to the study protocol and patients will not be dropped out because of intention
14 to treat. In the case an adverse event or a serious adverse event occurs, the blinded outcome assessor
15 will inform the principal investigator or responsible study personnel immediately.
16
17
18
19
20
21
22
23

24 *Termination of the study*
25

26 In the case of a preterminal termination of the study because of significant incidence of adverse events
27 evaluated by the DSMB, the sponsor (Medical University of Vienna) will notify the competent
28 authorities the end of the study including an appropriate justification. If the study will be terminated
29 because of safety reasons the European Medicines Agency (EMA) will be notified as well.
30
31
32
33
34
35
36

37 *Data monitoring*
38

39 Data monitoring will be performed by the Clinical Trials Coordination Centre of the Medical University
40 of Vienna, who are independent from the investigators and the sponsor and who have no competing
41 interests. Data monitoring will be performed in regular intervals after inclusion of 50 patients per study
42 site. The designated monitor will contact and visit the investigator on a regular basis and will be allowed
43 to have direct access to all source documents, which are needed to verify all CRF and eCRF entries and
44 other protocol-related documents provided that subject confidentiality is maintained in agreement with
45 legal regulations. It will be the monitors' responsibility to inspect the CRFs and eCRFs at regular
46 intervals according to the monitoring plan throughout the study, to verify the adherence to the protocol
47 and the completeness, consistency, and accuracy of the data being entered on them.
48
49
50
51
52
53
54
55
56
57
58
59

60 *Data Safety*

All hard-copy forms, such as CRFs, source data and informed consents will be stored in locked rooms within a secured area and are only accessible by investigators involved in the trial.

Access to data is strictly controlled and will only be provided to the sponsor (Medical University of Vienna), the study investigators, ethics committee (Ethic committee of the Medical University of Vienna), and if requested the Austrian Competent Authorities (Bundesamt für Sicherheit im Gesundheitswesen (BASG)).

Data will be stored after publishing of the trial and all of the sub-studies by Iron Mountain Austrian Archivierungs GmbH (Gewerbe parkstraße 3, 2282 Markgrafneusiedl, Austria) for a period of not less than twenty-five years in accordance with the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by the national laws.

Patient and Public involvement

No patient or public involvement.

Discussion

The RAPID-II trial will provide clinical evidence regarding the effects of desflurane, sevoflurane, and propofol on postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery.

The most recent and largest trial in over 1200 patients demonstrated that propofol-based anaesthesia was associated with a lower incidence of postoperative delirium within the first five days as compared to sevoflurane-based anaesthesia.¹⁶ However, they further showed that the long-term cognitive function – assessed via telephone interviews – was significantly better in the sevoflurane group as compared to the propofol group three years after surgery.¹⁶ Cao et al. suggested that the choice of isoflurane or desflurane instead of sevoflurane would have led to similar results.¹⁶ Nevertheless, it has to be emphasized that this is not based on any scientific evidence.

In fact, pharmacokinetic characteristics of desflurane lead to significantly faster elimination as compared to sevoflurane.^{34–36} Desflurane has a blood/gas coefficient of 0.45, which is the lowest of all available volatile anaesthetics.³⁴ Thus, the context-sensitive decrement time of desflurane is significantly faster as compared to sevoflurane.^{35,36} Specifically, the time until 90% of sevoflurane is eliminated increases significantly after two hours of administration, while the time of elimination of 90% of desflurane remains relatively constant.^{35,36} Some studies have shown that desflurane led to significantly faster extubation times, faster eye opening to verbal command, faster reciting of full name, and faster orientation as compared to sevoflurane.^{17–21} Furthermore, a recent pilot study showed that in patients, who received desflurane for major surgery, postoperative cognitive function assessed via Mini Mental State Examination (MMSE) was significantly higher after desflurane anaesthesia as compared to sevoflurane.³⁷ Interestingly, studies investigating different anaesthetics with a clinical meaningful neurological outcome are still lacking, specifically in regards to desflurane. Thus, the strength of our trial is that it will be the first adequately powered randomised study comparing the effects of desflurane on the incidence of postoperative delirium as compared to sevoflurane or propofol.

In addition, measuring anaesthetic depth by simply using the BIS value is not sufficient. In the study by Cao et al. only 70% of patients were monitored with BIS and the BIS values and not raw EEG or colour

1
2
3 spectral density array were used for the determination of anaesthetic depth.¹⁶ It has been shown that
4 during emergence, volatile anaesthetics induce higher power in frequencies above 15 Hz compared to
5 propofol resulting in higher BIS indices for this drug group.³⁸ Specific index values do not always
6 correlate with the same clinical state of consciousness. We therefore plan to further compare colour
7 spectral density arrays between the groups.
8
9
10
11
12

13
14
15 The use of volatile anaesthetics has been criticized in recent years due to their environmental effects.^{39,40}
16 We are aware that a discontinuation of desflurane has been proposed recently.⁴¹ These recommendations
17 are often based on calculations of the global warming potential of 100 years (GWP₁₀₀), which should be
18 used for gases with atmospheric lifetimes of at least 100 years.⁴² However, since the atmospheric lifetime
19 of desflurane is approximately 14 years, the GWP₁₀₀ formula is inadequate, which often leads to
20 overestimation of its global warming potential.^{42–44} Furthermore, propofol leads to CO₂ emissions and
21 water pollution, which has significant deleterious effects on global warming, which are often
22 underestimated.^{42,43,45} Therefore, it is of utmost importance to provide evidence on patient outcomes
23 before decisions with wide clinical implications will be made. The discontinuation of desflurane and the
24 choice of general anaesthetic in routine care should not be based solely on environmental reasons but
25 also should be supported by their clinical impact and evidence-based results.
26
27
28
29
30
31
32
33
34
35
36
37

38
39
40 This trial will have some limitations. Firstly, due to the different methods of administration and because
41 this is a large, multi-centre, pragmatic trial, blinding of the attending anaesthetists will not be suitable.
42 However, to provide equal depth of anaesthesia, dosage of anaesthetics will be standardized for all
43 patients with an aim of BIS values 40 to 60. Furthermore, DSA will be further analysed and compared
44 between the groups. To further limit possible bias, all postoperative outcomes will only be assessed by
45 study personnel blinded toward the randomly assigned group. Secondly, we will only include patients
46 planned for major noncardiac surgery. Furthermore, we will only include patients ≥ 65 years of age,
47 since the incidence of postoperative delirium is highest in this patient population.² Thus, the
48 generalisability for emergency surgery, cardiac surgery, and younger patients will be limited. Lastly,
49 some patients might be discharged from the hospital before the fifth postoperative day, limiting the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 delirium assessments. However, based on the current clinical standard of care, patients with delirium
4 are unlikely to be discharged from hospital. Thus, the number of patients with delirium missed in our
5 outcome assessment should be minimal.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In summary, the RAPID-II trial will be a multi-centre, observer-blinded, prospective, randomised clinical trial that is adequately powered to evaluate the effects of desflurane versus sevoflurane versus propofol for maintenance of anaesthesia on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery. The results of this trial might therefore provide evidence regarding the effects of anaesthetics on neurologic outcomes and more importantly will give clinicians guidance for the choice of general anaesthetics in highly vulnerable patients.

Trial Status

Actual protocol: Version 5.0, March 5, 2024. Patient recruitment started in September 2023.

Funding Statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The authors have no conflicts of interest.

Authors' contributions

AT, CR, EF, BK, BS: conceptualisation and study design; AT, CR, EF, AG: first draft of the manuscript; CE, KH, NA, NH, BH, OZ, DE, KMH, HL, ML, BR, SS, MS, GZ, FWZ, IE, CG, NI, MK, SR, BR, ST, MW: data collection; MF, AG: data management; AG: statistical analysis; AT, EF, BK, BS, CE, KH, NA, NH, BH, OZ, MF, AG, CR: editing and critical review of the manuscript; All authors read and approved the final manuscript. AT is the guarantor.

References

1. Humeidan ML, Reyes JPC, Mavarez-Martinez A, et al. Effect of Cognitive Prehabilitation on
2 the Incidence of Postoperative Delirium among Older Adults Undergoing Major Noncardiac
3 Surgery: The Neurobics Randomized Clinical Trial. *JAMA Surg.* 2021;156(2):148-156.
4 doi:10.1001/jamasurg.2020.4371
5. Li GH, Zhao L, Lu Y, et al. Development and validation of a risk score for predicting
6 postoperative delirium after major abdominal surgery by incorporating preoperative risk factors
7 and surgical Apgar score. *J Clin Anesth.* 2021;75(July):110408.
8 doi:10.1016/j.jclinane.2021.110408
9. Mrkobrada M, Chan MTV, Cowan D, et al. Perioperative covert stroke in patients undergoing
10 non-cardiac surgery (NeuroVISION): a prospective cohort study. *The Lancet.*
11 2019;394(10203):1022-1029. doi:10.1016/S0140-6736(19)31795-7
12. Daiello LA, Racine AM, Yun Gou R, et al. Postoperative Delirium and Postoperative
13 Cognitive Dysfunction: Overlap and Divergence. *Anesthesiology.* 2019;131(3):477-491.
14 doi:10.1097/ALN.0000000000002729
15. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. *The Lancet.*
16 2014;383(9920):911-922. doi:10.1016/S0140-6736(13)60688-1
17. Rudolph JL, Marcantonio ER. Postoperative Delirium: Acute change with long-term
18 implications. *Anesth Analg.* 2011;112(5):1202-1211. doi:10.1213/ANE.0b013e3182147f6d
19. Gleason LJ, Schmitt EM, Kosar CM, et al. Effect of delirium and other major complications on
20 outcomes after elective surgery in older adults. *JAMA Surg.* 2015;150(12):1134-1140.
21 doi:10.1001/jamasurg.2015.2606
22. Gou RY, Hsieh TT, Marcantonio ER, et al. One-Year Medicare Costs Associated with
23 Delirium in Older Patients Undergoing Major Elective Surgery. *JAMA Surg.* 2021;156(5):430-
24 442. doi:10.1001/jamasurg.2020.7260
25. Goldberg TE, Chen C, Wang Y, et al. Association of delirium with long-term cognitive
26 decline: A meta-analysis. *JAMA Neurol.* 2020;77(11):1373-1381.
27 doi:10.1001/jamaneurol.2020.2273

- 1
2
3 10. Mohanty S, Rosenthal RA, Russell MM, Neuman MD, Ko CY, Esnaola NF. Optimal
4 Perioperative Management of the Geriatric Patient: A Best Practices Guideline from the
5 American College of Surgeons NSQIP and the American Geriatrics Society. *J Am Coll Surg.*
6 2016;222(5):930-947. doi:10.1016/j.jamcollsurg.2015.12.026
- 7 11. Robinson TN, Raeburn CD, Tran Z V., Brenner LA, Moss M. Motor subtypes of postoperative
8 delirium in older adults. *Archives of Surgery.* 2011;146(3):295-300.
9 doi:10.1001/archsurg.2011.14
- 10 12. Kunicki ZJ, Ngo LH, Marcantonio ER, et al. Six-Year Cognitive Trajectory in Older Adults
11 Following Major Surgery and Delirium. *JAMA Intern Med.* 2023;183(5):442-450.
12 doi:10.1001/jamainternmed.2023.0144
- 13 13. Mei X, Zheng HL, Li C, et al. The Effects of Propofol and Sevoflurane on Postoperative
14 Delirium in Older Patients: A Randomized Clinical Trial Study. *Journal of Alzheimer's
15 Disease.* 2020;76(4):1627-1636. doi:10.3233/JAD-200322
- 16 14. Saller T, Hubig L, Seibold H, et al. Association between post-operative delirium and use of
17 volatile anesthetics in the elderly: A real-world big data approach. *J Clin Anesth.* 2022;83.
18 doi:10.1016/j.jclinane.2022.110957
- 19 15. Jiang JL, Zhang L, He LL, et al. Volatile Versus Total Intravenous Anesthesia on Postoperative
20 Delirium in Adult Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial.
21 *Anesth Analg.* 2023;136(1):60-69. doi:10.1213/ANE.0000000000006257
- 22 16. Cao SJ, Zhang Y, Zhang YX, et al. Delirium in older patients given propofol or sevoflurane
23 anaesthesia for major cancer surgery: a multicentre randomised trial. *Br J Anaesth.*
24 2023;131(2):253-265. doi:10.1016/j.bja.2023.04.024
- 25 17. Iannuzzi E, Iannuzzi M, Viola G, Cerulli A, Cirillo V, Chiefari M. Desflurane and sevoflurane
26 in elderly patients during general anesthesia: a double blind comparison. *Minerva Anestesiol.*
27 2005;71(4):147-155. http://www.ncbi.nlm.nih.gov/pubmed/15756155
- 28 18. Wang C, Li L, Xu H, Lv H, Zhang H. Effect of desflurane–remifentanil or sevoflurane–
29 remifentanil on early recovery in elderly patients: A meta-analysis of randomized controlled
30 trials. *Pharmazie.* 2019;74(4):201-205. doi:10.1691/ph.2019.8935

- 1
2
3 19. Yu H, Zhang L, Ma Y, Yu H. Early postoperative recovery in operating room after desflurane
4 anesthesia combined with Bispectral index (BIS) monitoring and warming in lengthy
5 abdominal surgery: A randomized controlled study. *BMC Anesthesiol.* 2018;18(1):1-7.
6
7 doi:10.1186/s12871-018-0577-6
8
9 20. Heavner JE, Kaye AD, Lin BK, King T. Recovery of elderly patients from two or more hours
10 of desflurane or sevoflurane anaesthesia. *Br J Anaesth.* 2003;91(4):502-506.
11
12 doi:10.1093/bja/aeg221
13
14 21. De Oliveira GS, Fitzgerald PC, Ahmad S, Jay Marcus R, McCarthy RJ. Desflurane/fentanyl
15 compared with sevoflurane/fentanyl on awakening and quality of recovery in outpatient
16 surgery using a Laryngeal Mask Airway: A randomized, double-blinded controlled trial. *J Clin*
17
18 *Anesth.* 2013;25(8):651-658. doi:10.1016/j.jclinane.2013.07.006
19
20 22. Taschner A, Fleischmann E, Horvath K, et al. Desflurane versus sevoflurane anesthesia and
21 postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery
22 – A prospective, randomized, observer-blinded, clinical trial. *J Clin Anesth.* 2024;98:111576.
23
24 doi:10.1016/j.jclinane.2024.111576
25
26 23. Hamadnalla H, Sessler DI, Troianos CA, et al. Optimal interval and duration of CAM-ICU
27 assessments for delirium detection after cardiac surgery. *J Clin Anesth.*
28
29 2021;71(March):110233. doi:10.1016/j.jclinane.2021.110233
30
31 24. Marcantonio ER, Ngo LH, Connor MO, et al. 3D-CAM: Derivation and Validation of a 3-
32 Minute Diagnostic Interview for CAM-defined Delirium. *Ann Intern Med.* 2014;161(8):554-
33 561. doi:10.7326/M14-0865.3D-CAM
34
35 25. Evers LA, Silbert BS. Postoperative cognitive dysfunction and noncardiac surgery. *Anesth*
36
37 *Analg.* 2018;127(2):496-505. doi:10.1213/ANE.0000000000003514
38
39 26. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction
40 in the elderly: ISPOCD1 study. *Lancet.* 1998;351(9106):857-861. doi:10.1016/S0140-
41 6736(97)07382-0
42
43 27. Krishnan K, Rossetti H, Hynan LS, et al. Changes in Montreal Cognitive Assessment Scores
44 Over Time. *Assessment.* 2017;24(6):772-777. doi:10.1177/1073191116654217
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28. Tan HH, Xu J, Teoh HL, et al. Decline in changing montreal cognitive assessment (MoCA)
4 scores is associated withpost-stroke cognitive decline determined by a formal
5 neuropsychological evaluation. *PLoS One.* 2017;12(3). doi:10.1371/journal.pone.0173291
6
7 29. Pendlebury ST, Welch SJ V, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone
8 assessment of cognition after TIA and stroke : TICSm and telephone MoCA vs face-to-face
9 MoCA and neuropsychological battery. *Stroke.* 2013;44(1):227-229.
10
11 15 doi:10.1161/STROKEAHA.112.673384.Telphone
12
13 16
14 17 30. Zietemann V, Kopczak A, Müller C, Wollenweber FA, Dichgans M. Validation of the
15 telephone interview of cognitive status and telephone montreal cognitive assessment against
16 detailed cognitive testing and clinical diagnosis of mild cognitive impairment after stroke.
17
18 24 *Stroke.* 2017;48(11):2952-2957. doi:10.1161/STROKEAHA.117.017519
19
20 25
21 26 31. Takeuchi M, Takeuchi H, Fujisawa D, et al. Incidence and risk factors of postoperative
27 delirium in patients with esophageal cancer. *Ann Surg Oncol.* 2012;19(12):3963-3970.
28
29 32 doi:10.1245/s10434-012-2432-1
30
31 33 32. Robinson TN, Raeburn CD, Tran Z V., Angles EM, Brenner LA, Moss M. Postoperative
34 delirium in the elderly: Risk factors and outcomes. *Ann Surg.* 2009;249(1):173-178.
35
36 37 doi:10.1097/SLA.0b013e31818e4776
38
39 33. Wildes TS, Mickle AM, Abdallah A Ben, et al. Effect of electroencephalography-guided
40 anesthetic administration on postoperative delirium among older adults undergoing major
41 surgery the engages randomized clinical trial. *JAMA - Journal of the American Medical
42 Association.* 2019;321(5):473-483. doi:10.1001/jama.2018.22005
43
44 47 34. Wissing H, Kuhn I, Rietbrock S, Fuhr U. *Pharmacokinetics of Inhaled Anaesthetics in a
48 Clinical Setting: Comparison of Desflurane, Isoflurane and Sevoflurane †.* Vol 84.; 2000.
49
50 51 35. Lockwood G. Theoretical context-sensitive elimination times for inhalation anaesthetics. *Br J
52 Anaesth.* 2010;104(5):648-655. doi:10.1093/bja/aeq051
53
54 55 36. Bailey JM. Context-Sensitive Half-Times and Other Decrement Times of Inhaled Anesthetics.
56 *Anesth Analg.* 1997;85:681-686.
57
58
59
60


- 1
2
3 37. Tachibana S, Hayase T, Osuda M, Kazuma S, Yamakage M. Recovery of postoperative
4 cognitive function in elderly patients after a long duration of desflurane anesthesia: a pilot
5 study. *J Anesth.* 2015;29(4):627-630. doi:10.1007/s00540-015-1979-y
6
7 38. Lipp M, Schneider G, Kreuzer M, Pilge S. Substance-dependent EEG during recovery from
8 anesthesia and optimization of monitoring. *J Clin Monit Comput.* 2024;38(3):603-612.
9 doi:10.1007/s10877-023-01103-4
10
11 39. White SM, Shelton CL. Abandoning inhalational anaesthesia. *Anaesthesia.* 2020;75(4):451-
12 454. doi:10.1111/anae.14853
13
14 40. Ryan SM, Nielsen CJ. Global warming potential of inhaled anesthetics: Application to clinical
15 use. *Anesth Analg.* 2010;111(1):92-98. doi:10.1213/ANE.0b013e3181e058d7
16
17 41. Van Norman GA, Jackson S. The anesthesiologist and global climate change: an ethical
18 obligation to act. *Curr Opin Anaesthesiol.* 2020;33(4):577-583.
19 doi:10.1097/ACO.0000000000000887
20
21 42. Slingo JM, Slingo ME. The science of climate change and the effect of anaesthetic gas
22 emissions. *Anaesthesia.* Published online 2024. doi:10.1111/anae.16189
23
24 43. Tapley P, Patel M, Slingo M. Abandoning inhalational anaesthesia. *Anaesthesia.*
25 2020;75(9):1257-1258. doi:10.1111/anae.15142
26
27 44. Pierrehumbert RT. Short-lived climate pollution. *Annu Rev Earth Planet Sci.* 2014;42:341-379.
28 doi:10.1146/annurev-earth-060313-054843
29
30 45. Kostrubiak M, Vatovec CM, Dupigny-Giroux LA, et al. Water Pollution and Environmental
31 Concerns in Anesthesiology. *J Med Syst.* 2020;44(9):169. doi:10.1007/s10916-020-01634-
32 2/Published
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Captions for Figures**
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study procedure

For peer review only

1
2 **Figure 1. Study procedure**
3
4
5
6



BIS, bispectral index; ICU, intensive care unit.

1
2
3
4
5
6
7
8
9
10
11 **Supplementary Online Content**

12 **eAppendix 1.** List of investigators RAPID II Trial

13 **eAppendix 2.** Definition of moderate- to high-risk major noncardiac surgery

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 This supplementary material has been provided by the authors to give readers additional information
57 about their work.
58
59
60

eAppendix 1. List of investigators RAPID II Trial

1. Medical University of Vienna: Nikolas Adamowitsch; David Emler; Edith Fleischmann;
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Melanie Fraunschiel; Alexandra Graf; Nicole Hantakova; Beatrix Hochreiter; Kira Margarete Hörl; Katharina Horvath; Barbara Kabon; Helena Langthaler; Magdalena List; Christian Reiterer; Barbara Rossi; Simon Schallmeiner; Mathias Stiefsohn; Alexander Taschner; Giulia Zanvettor; Florian Wolfgang Zenz; Oliver Zotti;
2. Medical University of Innsbruck: Christine Eckhardt; Iris Emshoff; Christoph Geiger; Nicole Innerhofer; Mario Kofler; Sasa Rajsic; Beatrix Reyer; Barbara Sinner; Susanne Trübsbach; Melanie Widmann;

eAppendix 2. Definition of moderate- to high-risk major noncardiac surgery

We defined the following surgeries to meet the criteria for moderate- to high-risk major noncardiac surgery:

- Major general surgery: complex visceral resection, partial or total colectomy, gastrectomy, partial liver resection, pancreas resection, oesophageal resection, anterior rectal resection, retroperitoneal tumour resection, small bowel resection
- Major urologic surgery: prostatectomy, cystectomy, nephrectomy, retroperitoneal tumour resection, major open lymphadenectomy
- Major gynaecologic surgery: retroperitoneal tumour resection, exenteration, cytoreduction surgery, open hysterectomy
- Major orthopaedic surgery: total hip replacement, partial hip replacement, total knee replacement

BMJ Open

The effect of desflurane, sevoflurane, or propofol on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery: study protocol for a prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2024-092611.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Oct-2024
Complete List of Authors:	Taschner, Alexander; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Fleischmann, Edith; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Kabon, Barbara; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Sinner, Barbara; Medical University Innsbruck, Department of Anaesthesia and Intensive Care Eckhardt, Christine; Medical University Innsbruck, Department of Anaesthesia and Intensive Care Horvath, Katharina; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Adamowitsch, Nikolas; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Hantakova, Nicole; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Hochreiter, Beatrix; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Zotti, Oliver; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine Fraunschiel, Melanie; Medical University of Vienna, IT Services and strategic information management Graf, Alexandra; Medical University of Vienna, Institute of Medical Statistics, Centre for Medical Data Science Reiterer, Christian; Medical University of Vienna, Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of General Anaesthesia and Intensive Care Medicine

Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Delirium, Adult anaesthesia < ANAESTHETICS, ANAESTHETICS, Randomized Controlled Trial

SCHOLARONE™
Manuscripts

1
2
3
4
5 **The effect of desflurane, sevoflurane, or propofol on the incidence of postoperative delirium in**
6 **older adults undergoing moderate- to high-risk major noncardiac surgery: study protocol for a**
7
8 **prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)**

9
10
11
12
13
14
15
16
17 Alexander Taschner¹; Edith Fleischmann¹; Barbara Kabon¹; Barbara Sinner²; Christine Eckhardt²;
18 Katharina Horvath¹; Nikolas Adamowitsch¹; Nicole Hantakova¹; Beatrix Hochreiter¹; Oliver Zotti¹;
19
20 Melanie Fraunschiel³; Alexandra Graft⁴; Christian Reiterer^{1*} for the RAPID-II investigator group
21
22
23 (eAppendix 1 in the Online Supplement)

24
25
26
27
28
29
30 ¹ Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain
31 Medicine, Division of General Anaesthesia and Intensive Care Medicine, 1090 Vienna, Austria

32
33
34 ² Department of Anaesthesia and Intensive Care, Medical University Innsbruck, 6020 Innsbruck,
35 Austria

36
37
38 ³ IT Services and strategic information management, Medical University of Vienna, 1090 Vienna,
39 Austria

40
41
42 ⁴ Institute of Medical Statistics, Centre for Medical Data Science, Medical University of Vienna, 1090
43 Vienna, Austria

44
45
46 *** Correspondence to:**

47
48
49 Prof. Christian Reiterer, M.D., Ph.D.

50
51 Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of
52 Vienna; Spitalgasse 23, 1090 Vienna, Austria.

53
54 christian.reiterer@meduniwien.ac.at; Phone: 0043 1 40400 20760

55
56
57 **Word count:** 4309 words

Abstract

Introduction: The effect of different anaesthetics on the incidence of postoperative delirium is still not entirely clear. Therefore, we will evaluate the effect of desflurane versus sevoflurane versus propofol for maintenance of anaesthesia on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery. We will further compare the incidences of delayed neurocognitive recovery, long-term postoperative neurocognitive disorder, postoperative nausea and vomiting between the groups.

Methods and analysis: In this multi-centre, prospective, observer-blinded, randomised controlled clinical trial we will include 1332 patients ≥ 65 years of age undergoing moderate- to high-risk major noncardiac surgery lasting at least two hours. Patients will be randomly 1:1:1 assigned to receive desflurane, sevoflurane or propofol for anaesthesia. Maintenance of anaesthesia will be performed in a goal-directed manner using processed electroencephalography with an intraoperative goal of bispectral index 40 to 60. Our primary outcome will be the incidence of postoperative delirium within the first five postoperative days. Postoperative delirium will be assessed using the 3D-Confusion Assessment Method (3D-CAM) or CAM-ICU in the morning and evening of the first five postoperative days by blinded study personnel. The primary outcome, the incidence of postoperative delirium, will be compared between the three study groups using a Chi-Square-test. Furthermore, a logistic regression model for the incidence of postoperative delirium will be performed accounting for randomised group as well as other pre-defined confounding factors.

Ethics and dissemination: This clinical trial has been approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria. The results of this trial will be published in a peer-reviewed journal.

Trial registration:

ClinicalTrials.gov NCT05990790;

<https://clinicaltrials.gov/study/NCT05990790?term=NCT05990790&rank=1>

1
2
3 **Strengths and limitations of this study:**
4

- 5 - This will be a multi-centre prospective trial powered to detect a 10% absolute risk reduction in
6 postoperative delirium between desflurane, sevoflurane, and propofol.
7
8 - This trial will achieve good internal validity due to randomisation and blinding of outcome
9 assessors as well as high external validity due to the large sample size and the inclusion of many
10 types of noncardiac surgery.
11
12 - Postoperative delirium will be assessed in the morning and evening for the initial five
13 postoperative days according to the current recommendations.
14
15 - Due to the different methods of administration of the three anaesthetics, blinding of the
16 attending anaesthetists will not be performed.
- 17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Postoperative delirium is a major complication after cardiac and noncardiac surgery and occurs more often in older adults.^{1–3} Based on previous observational studies, the incidence of postoperative delirium in older adults is between 20 and 45%.^{4–6} Delirium is associated with prolonged stay in intensive care units (ICU) and hospitalisation, leading to higher hospitalisation costs, which are as high as costs caused by cardiovascular complications.^{4,5,7,8} More importantly, postoperative delirium is associated with accelerated long-term neurocognitive decline and dementia and further increases morbidity and mortality.^{4,5,9–12} In this context, the American College of Surgeons and the American Society of Anesthesiologists have identified the prevention of postoperative delirium as a public health priority.^{8,10} Nevertheless, a clear consensus on perioperative anaesthesiologic management of older adults undergoing major noncardiac surgery with the specific goal of preventing postoperative delirium has not been established yet.¹⁰

Some previous studies evaluated the effects of volatile versus intravenous anaesthesia on the incidence of postoperative delirium.^{13–16} However, these studies mostly compared sevoflurane versus propofol anaesthesia and showed conflicting results.^{13–16} The most recent and largest randomised trial showed a significantly lower incidence of postoperative delirium after propofol-anaesthesia as compared to sevoflurane-anaesthesia.¹⁶ However, so far data regarding the effects of desflurane as compared to sevoflurane and propofol on the incidence of postoperative delirium is scarce. While it has been shown previously that desflurane anaesthesia leads to significantly faster immediate postoperative recovery as compared to sevoflurane,^{17–21} we could not observe in one of our previous studies a significant difference immediate postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery.²² Nevertheless, the effect of desflurane versus sevoflurane versus propofol on the incidence of postoperative delirium in older adults undergoing major noncardiac surgery is still unclear.

Therefore, we will test our primary hypothesis that anaesthesia with desflurane will be associated with a significantly lower incidence of postoperative delirium within the first five postoperative days as compared to anaesthesia with sevoflurane or anaesthesia with propofol in older adults undergoing

1
2
3 moderate- to high-risk major noncardiac surgery lasting at least two hours. We will further test the
4 secondary hypotheses that anaesthesia with desflurane will be associated with significantly lower
5 incidences of delayed neurocognitive recovery and long-term neurocognitive disorder as compared to
6 anaesthesia with sevoflurane or anaesthesia with propofol.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods and Analysis

Trial Design

We will conduct the RAPID-II trial, a multi-centre, observer-blinded, prospective, randomised, three-arm parallel arm clinical trial at the Medical University of Vienna and the Medical University Innsbruck. All members of the RAPID-II investigator group are listed in Online Supplement 1. We will include 1332 patients ≥ 65 years of age undergoing moderate- to high-risk major noncardiac surgery. The trial was approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria on the 19th of June 2023 (CTIS Reference number: 2023-503717-30-00). We started patient enrolment on the 3rd of September 2023 and currently the estimated date of primary completion is 31st of December 2027 and the estimated study completion date is 31st of December 2028.

Study population

The inclusion and exclusion criteria are presented in Table 1. Study personnel will screen the surgical schedule the day before surgery and check for eligibility. Definitions of surgeries, which will be included are listed in eAppendix 2 of the Online Supplement. They will further approach eligible patients to obtain informed consent before surgery. Previous experience showed that 6-8 patients will be eligible per week. Therefore, we assume a period of 3-4.5 years to complete patient recruitment for this study.

Table 1: Inclusion and Exclusion Criteria

Inclusion criteria (1-3)

1. Provided written informed consent
2. ≥ 65 years of age
3. Scheduled for elective major non-cardiac surgery with estimated time of surgery ≥ 2 hours

Exclusion criteria (1-9)

1. Patients undergoing emergency surgery
2. $BMI > 45\text{kg.m}^{-2}$
3. History of diagnosed dementia
4. Language, vision, or hearing impairments that may compromise cognitive assessments
5. History of malignant hyperthermia
6. History of structural muscle disease
7. History of organ transplantation (kidney, liver, lung, heart)
8. Patients undergoing hyperthermic intraperitoneal chemotherapy surgery

1
2
3 9. ICU patients undergoing surgery
4
5
6

7 BMI, body mass index; ICU, intensive care unit.
8
9

10 *Data management*
11
12 Electronic data will be recorded in the data management system “ClinCase”, Version 2.7.0.12 hosted by
13
14 IT Services & strategic information management of the Medical University of Vienna, Vienna, Austria.
15
16

17
18 *Randomisation and blinding*
19
20 We will randomise patients within one hour before surgery. We will use the online randomisation
21
22 programme “Randomizer” (Randomizer, Medical University of Graz, Graz, Austria:
23
24 <https://www.meduniwien.ac.at/randomizer/web/login.php>) provided by the IT Services & strategic
25
26 information management Department of the Medical University of Vienna, 1090 Vienna, Austria.
27
28 Randomisation will be performed with permuted blocks stratified by study centre, sex, and age (65-
29
30 79 years, ≥80 years). Randomisation will only be performed by registered personnel, who are not
31
32 involved in postoperative outcome assessments. The attending anaesthetists will be informed about the
33
34 randomly assigned group and will not be involved in postoperative outcome assessments. Only study
35
36 personnel responsible for postoperative outcome assessments will be blinded regarding the randomly
37
38 assigned group. Patients will be randomised 1:1:1 to the following three groups:
39
40

41 **Desflurane group:** after induction of anaesthesia, anaesthesia will be maintained with goal-directed
42
43 administration of desflurane with an intraoperative goal of bispectral index (BIS) 40 to 60.
44

45 **Sevoflurane group:** after induction of anaesthesia, anaesthesia will be maintained with goal-directed
46
47 administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 40 to 60.
48

49 **Propofol group:** after induction of anaesthesia, anaesthesia will be maintained with a goal-directed
50
51 continuous infusion of propofol with an intraoperative goal of bispectral index (BIS) 40 to 60.
52
53

54
55 *Anaesthesia protocol*
56
57
58

All patients will receive an ECG, blood pressure and peripheral oxygen saturation monitoring. An arterial line and/or central venous line will be placed and monitored at the discretion of the attending anaesthetist according to local clinical standard of care.

After endotracheal intubation, anaesthesia will be maintained using desflurane or sevoflurane in a mixed oxygen carrier gas or continuous propofol infusion according to the allocated randomised group. We will use the first 10 minutes after intubation to set anaesthesia to the target BIS value. Desflurane, sevoflurane and propofol respectively will be titrated and adjusted using processed electroencephalography for a target BIS of 40 to 60 throughout surgery.

Fentanyl and remifentanil, respectively, will be administered at the discretion of the attending anaesthetist. We will give additional muscle relaxation to maintain 1-2 mechanical twitches in response to supra-maximal stimulation (Train-of-four stimulation, target <75%). For mechanical ventilation, we will maintain an inspiratory FiO_2 between 0.3 and 0.5 to achieve a SpO_2 of at least 93% or pO_2 of >80mmHg. Tidal volumes will be set between 6 and 8mL lean body weight to maintain end-tidal CO_2 within 35-40mmHg. Positive end-expiratory pressure will be set at 5mmHg or higher according to the patients' requirements. Intraoperative PONV prophylaxis will be administered at the discretion of the attending anaesthetist. We will actively warm patients with convective warming to maintain perioperative normothermia. Intraoperative mean arterial pressure will be held at a minimum of 65mmHg. Intraoperative fluid and vasopressor management will be performed at the discretion of the attending anaesthetist according to local clinical standard of care. We will maintain a haemoglobin of at least 8g.dL⁻¹. Anaesthesiologic adjuvants, e.g. esketamine, clonidine, atropine, dexmedetomidine, midazolam, and scopolamine should be avoided. The postoperative management of medication will be done according to the attending physicians.

At the end of surgery, we will stop the administration of desflurane, sevoflurane, and propofol respectively. In the case of planned intubated transfer to intensive care units (ICU) after surgery, desflurane or sevoflurane will be stopped and propofol administration will be started (Figure 1).

Outcomes

Our primary outcome will be the incidence of postoperative delirium within the first five postoperative days between the desflurane, sevoflurane, and propofol groups.

Our secondary outcomes will include the incidence of delayed neurocognitive recovery, postoperative need of supplemental oxygen, length of stay in the ICU, incidence of postoperative nausea and vomiting (PONV) in the early and late postoperative periods, intraoperative hypotension, and death within the first five postoperative days.

Our exploratory outcomes will include the number of days at home up to 30 days after surgery, long-term postoperative neurocognitive disorder one year after surgery, and postoperative area under the curve of plasma concentrations of inflammatory biomarkers (C-reactive protein (CRP), Interleukin-6 (IL-6), Procalcitonin (PCT)), cardiac biomarkers (Troponin T, N-terminal pro-brain natriuretic peptide (NT-proBNP), Copeptin), and neuronal injury biomarkers (S100-B, Neuron-specific enolase (NSE)). Study specific blood samples will be drawn shortly before induction of anaesthesia, within two hours after surgery and on the second postoperative day. Furthermore, we will assess one-year all-cause mortality one year after surgery in all patients.

In a sub-study, we will compare differences between preoperative and postoperative concentrations of advanced neuro-biomarkers including neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) between the groups.

A detailed description of primary, secondary, exploratory, and sub-study specific outcomes and their assessments is shown in Table 2.

Table 2: Outcome assessments

Outcome	Measurements	Timepoint
<i>Primary Outcome</i>		
Postoperative delirium	3D-CAM/CAM-ICU	Evening on the day of surgery and morning and evening of the first five postoperative days
<i>Secondary Outcomes</i>		
Delayed neurocognitive recovery	DSST, TMT Part A, TMT Part B	Preoperative, postoperative day 5

Need of supplemental oxygen	Litres.minute ⁻¹	During PACU/ICU stay
Length of stay in ICU	Number of days at ICU	During ICU stay
Early PONV	Patient assessment of PONV episode	First two hours after surgery
Late PONV	Patient assessment of PONV episode	Evening on the day of surgery and morning and evening of the first five postoperative days
Intraoperative hypotension	Intraoperative mean arterial pressure + cumulative catecholamine administration	Intraoperative
Death within 5 days		First five postoperative days

Exploratory Outcomes

Days at home up to 30 days after surgery (DAH ₃₀)	Phone Follow-Up, patient records	30 days after surgery
Long-term neurocognitive disorder	MoCA test via phone Follow-Up	Preoperative, 1 year after surgery
AUC of inflammatory biomarkers	CRP, IL-6, PCT	Preoperative, within two hours after surgery, postoperative day 2
AUC of cardiac biomarkers	Troponin T, NT-proBNP, Copeptin	Preoperative, within two hours after surgery, postoperative day 2
AUC of neuronal injury biomarkers	S100-B, NSE	Preoperative, within two hours after surgery, postoperative day 2
One-year all-cause mortality		One year after surgery

Sub-Study Outcomes

Advanced Neuro-Biomarkers	NfL, GFAP	Preoperative, postoperative day 3
---------------------------	-----------	-----------------------------------

CAM, confusion assessment method; ICU, intensive care unit; dNR, delayed neurocognitive recovery; DSST, digit symbol substitution test; TMT, trail making test; PACU, post-anaesthesia care unit; PONV, postoperative nausea and vomiting; DAH₃₀, number of days at home in the first month after surgery; NCD, neurocognitive disorder; MoCA, Montreal Cognitive Assessment; AUC, area under the curve; CRP, C-reactive protein; IL-6, Interleukin-6; PCT, Procalcitonin; NT-proBNP, N-terminal pro-brain-natriuretic peptide; NSE, neuron-specific enolase; NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein.

Measurements

Demographic and morphometric data

1
2 Basic data including age, sex, body mass index, and ASA physical status, will be recorded. We will
3 record medical history including comorbidities, long-term medication, and history of tobacco or alcohol
4 use and type of surgery.
5
6

7
8
9 Perioperative data
10
11

12 Routine intra- and postoperative anaesthesia specific data will be extracted from our electronic
13 anaesthesia records. Intraoperative data will include arterial blood gas analysis, durations of anaesthesia
14 and surgery, intraoperative fluid management, intraoperative medication, vasopressors, and
15 haemodynamic data.
16
17

18 We will further record inspiratory and expiratory concentrations of the administered volatile anaesthetic
19 and intraoperative amount of propofol. Intraoperative BIS data (BISTM, Medtronic[®], Meerbusch,
20 Germany) including BIS values and density spectral array (DSA) will be recorded and extracted directly
21 from the BIS monitor.
22
23

24 Postoperative pain will be recorded based on the numeric pain rating scale (NRS) in the PACU, ICU,
25 and on the ward twice daily within the first five postoperative days. We will record the overall amount
26 of piritramide, non-steroidal analgesics, duration of epidural anaesthesia, and the amount of co-
27 analgesics administered at the PACU, ICU, or on the ward within the first five postoperative days.
28
29

30
31 Outcome measurements
32
33

34 All postoperative outcome assessments will be performed by trained study personnel, who are blinded
35 to the assigned randomised group.
36
37

38 For our primary outcome, we will perform the 3D-confusion assessment method (3D-CAM) evaluations
39 starting on the evening of the day of surgery (6 p.m. – 10 p.m.). Following 3D-CAM evaluations will
40 be performed twice daily – in the mornings (5 a.m. – 11 a.m.) and evenings (6 p.m. – 10 p.m.) for the
41 following five postoperative days if patients are still hospitalised.^{23,24} In patients in the ICU, we will
42 perform CAM-ICU evaluations.^{23,24} Postoperative delirium will be defined as occurrence of at least one
43 positive 3D-CAM or CAM-ICU assessment in the first five postoperative days.
44
45

For the assessment of delayed neurocognitive recovery, we will perform digit symbol substitution tests (DSST), trail making test (TMT) part A and part B before surgery and on the fifth postoperative day if the patients are still hospitalised.^{25,26} For the TMT the time until test completion and the number of mistakes will be recorded. If the patients are intubated on the fifth postoperative day, the assessments will be postponed for two days. Delayed neurocognitive recovery will be defined in accordance with the ISPOPOCD-1 study when a patient has a Z-score on two or all tests or the combined Z-score is below -1.96 standard deviation.²⁶

For the assessment of neurocognitive disorder, we will further perform an adapted Montreal Cognitive Assessment (MoCA) test (telephone MoCA) before surgery and one year after surgery.²⁷⁻³⁰ Postoperative neurocognitive disorder will be defined as a decrease of two points or more from baseline values.²⁷⁻³⁰

DSST, TMT, 3D-CAM, CAM-ICU, and MoCA tests will be performed only by trained and blinded study personnel. PONV will be assessed on the evening of the day of surgery and in the morning and evening of the following five days. PONV will be defined as subjective symptoms of nausea and/or occurrence of vomiting at each timepoint. Oxygen supplementation will be recorded by number of litres.minute⁻¹ oxygen administered for SpO₂ ≥93% at PACU or ICU respectively. Furthermore, we will record the intraoperative use of vasopressors. We will record the duration of stay in the ICU in all patients. Phone follow-ups will be performed in all patients 30 days after surgery to determine the number of days at home up to 30 days after surgery and one year after surgery to perform the MoCA tests.

Study specific blood samples will include CRP, IL-6, PCT, Troponin T, NT-proBNP, Copeptin, NSE, S100-B, NfL, and GFAP. All laboratory parameters will be measured at the Department of Laboratory Medicine at the Medical University of Vienna and at the Department of Laboratory Medicine at the Medical University Innsbruck respectively. Blood samples will be treated with standard of care to provide best accuracy of measurement. Study specific blood samples of CRP, IL-6, PCT, Troponin T, NT-proBNP, Copeptin, NSE, and S100-B will be drawn shortly before induction of anaesthesia, within two hours after surgery and on the second postoperative day. Sub-study specific blood samples of NfL

1
2 and GFAP will be collected shortly before induction of anaesthesia and on the third postoperative day.
3
4

5 Sub-study specific blood samples will then be centrifuged and stored.
6
7
8

9 *Statistical analysis*
10

11 Data analysis
12

13 Baseline characteristics such as age, sex, ASA physical status, history of tobacco use, comorbidities,
14 long-term medication, and type of surgery will first be analysed descriptively. Descriptive statistics will
15 be calculated overall and separately for the three groups. Continuous variables will be summarised using
16 means, standard deviations, median, and interquartile ranges. Categorical data will be summarised using
17 absolute numbers and percentages.
18
19

20 Our primary outcome, the incidence of postoperative delirium, will be described in a descriptive way
21 using absolute numbers and percentages per study group. First, we will compare the incidence of
22 postoperative delirium between the three groups using a Chi-Square-test. Furthermore, a logistic
23 regression model for the incidence of postoperative delirium will be performed accounting for
24 randomised group as well as other confounding factors (e.g. age, BMI, ASA physical status, duration of
25 anaesthesia, additional epidural/regional anaesthesia, history of cerebrovascular disease). All three
26 groups will be analysed together in the logistic regression model and the pairwise comparison will be
27 conducted within the model. Patients, who die within the first five postoperative days will be excluded
28 from the primary analysis of our trial, unless positive delirium assessment were performed before
29 patients' death. As sensitivity analysis, to additionally account for death within 5 days after surgery, a
30 logistic regression model for the probability of the combined endpoint (postoperative delirium or death)
31 will be performed accounting for randomised group and other possible confounding factors.
32 Significance levels for the primary outcome will be used as described in the sample size calculation
33 section to account for the two interim analyses and the pairwise group comparisons to retain an overall
34 level for the type I error of 0.05
35
36

37 All analyses will be conducted on the ITT population, defined as all randomized patients, who received
38 one of the study drugs, even if the patient does not receive the correct treatment, or otherwise does not
39 follow the protocol. In addition to intention to treat analyses also per-protocol analyses will be performed
40
41

for the primary and secondary parameters. This analysis set comprises all subjects, who received one of the study drugs and did not violate the protocol in a way that might affect the evaluation of the effect of the study drug(s) on the primary objective, i.e., without major protocol violations.

The secondary outcome, the incidence of delayed neurocognitive recovery, will be evaluated between the study groups using a Chi-Square-test. Furthermore, a logistic regression model for the probability of delayed neurocognitive recovery will be performed accounting for randomised group as well as other possible confounding factors.

The secondary outcome, the number of litres of administered supplemental oxygen in PACU or ICU to achieve a $\text{SpO}_2 \geq 93\%$ will be compared between the study groups using Mann-Whitney-U tests.

The secondary outcome, the length of stay in the ICU, will be compared between the groups using a competing risk model for time to discharge from ICU and death as competing event accounting for study group as well as other possible confounding factors.

The secondary outcomes, incidences of PONV in the early and late postoperative period, will be evaluated between the groups using Chi-Square-tests. Furthermore, logistic regression models for the incidences of PONV in the early and late postoperative period will be performed.

The secondary outcome, intraoperative duration of $\text{MAP} < 65\text{mmHg}$ and the overall intraoperatively administered amount of catecholamines, will be compared between the groups using Mann-Whitney-U tests.

The secondary outcome, death within five days after surgery, will be compared between the groups using a Chi-Square-test. Furthermore, a logistic regression model for the probability of death will be performed.

The exploratory outcome, number of days at home up to 30 days after surgery, will be compared between the groups using Mann-Whitney-U tests. The exploratory outcome, incidence of neurocognitive disorder one year after surgery, will be compared using Chi-Square-tests. As exploratory outcomes, area under the curves of perioperative inflammatory biomarkers, cardiac biomarkers, and neuronal injury biomarkers, will be calculated and compared between the groups using Mann-Whitney-U tests. Lastly, probability of all-cause death within one year after surgery will be presented between the groups using Kaplan-Meier curves. For secondary and exploratory outcomes, a significance level of 0.05 is used.

Sample size calculation

We estimated the number of patients required for this trial based on previous studies, which showed that the incidence of postoperative delirium in older adults undergoing major abdominal surgery lies between 5–50%,^{5,31,32} whereas the largest study reported an incidence of 25%.³³ Using a conservative approach, we assumed the incidence of postoperative delirium at about 25%. A reduction of 10% points was assumed to be clinically relevant (25% versus 15%).

Two interim analyses, one after 1/3 and one after 2/3 of recruitment are pre-planned. To correct for the comparison of the three groups, Bonferroni-correction was applied resulting in a two-sided overall significance level of 0.0167 (0.05/3 for three comparisons). To further correct for the two interim-analyses (three total analyses including final analysis), the Hwang-Shih-DeCani spending function for group sequential designs (with associated parameter -4) was used resulting in a nominal alpha level of 0.001 for the first interim analysis, 0.004 for the second interim analysis, and 0.015 for the final analysis to control the overall significance level of 0.0167 for each of the three group comparisons.

Using a group sequential z-test and assuming an odds ratio of 0.529 (for proportions of 0.25 as compared to 0.15), we calculated a needed sample size of 431 patients per group to achieve a power of 0.9.

We assumed a drop-out rate of 3% (including patients, who die within the first five postoperative days), resulting in a needed sample size of 1332 patients (444 patients per group).

The sample size calculation was performed using NQuery 8.

Data safety monitoring board

The following experienced researchers will comprise the Data Safety Monitoring Board (DSMB): Prof. Dr. Eva Base (Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Division of Cardiothoracic and Vascular Anaesthesia, Medical University of Vienna, Austria), Prof. Dr. Michael Wolzt (Department of Clinical Pharmacology, Medical University of Vienna, Austria), Prof. Dr. Markus Zeitlinger (Department of Clinical Pharmacology, Medical University of Vienna, Austria), Prof. Dr. Gerd Silberhumer (Department of General Surgery, Medical University of Vienna, Austria).

1
2
3 Patients' safety will be monitored through the data and safety monitoring board. The DSMB will
4 evaluate adverse events (AEs, SAEs, SUSARs, ADR) for the two pre-planned interim analyses. In detail,
5 the DSMB will evaluate adverse events from 444 patients and 888 patients after all data are available.
6 It will be the responsibility of this committee to alert the local ethics committee via letter of any harmful
7 effects in one of the study groups. This committee, along with the local ethics committee will have the
8 exclusive authority to stop the study either for futility, harm, or clear benefit. Any morbidity potentially
9 related to the study protocol will be reported to the ethics committee.
10
11
12
13
14
15
16

17 18 19 *Emergency unblinding and termination of the study drug*

20 Attending anaesthesiologists will not be blinded for respective anaesthetic agents. In the case of
21 discontinuation or change of the randomly assigned group, assessments of postoperative outcomes will
22 be continued according to the study protocol and patients will not be dropped out because of intention
23 to treat. In the case an adverse event or a serious adverse event occurs, the blinded outcome assessor
24 will inform the principal investigator or responsible study personnel immediately.
25
26
27
28
29
30
31
32
33
34

Termination of the study

35 In the case of a preterminal termination of the study because of significant incidence of adverse events
36 evaluated by the DSMB, the sponsor (Medical University of Vienna) will notify the competent
37 authorities the end of the study including an appropriate justification. If the study will be terminated
38 because of safety reasons the European Medicines Agency (EMA) will be notified as well.
39
40
41
42
43
44

45 46 47 *Data monitoring*

48 Data monitoring will be performed by the Clinical Trials Coordination Centre of the Medical University
49 of Vienna, who are independent from the investigators and the sponsor and who have no competing
50 interests. Data monitoring will be performed in regular intervals after inclusion of 50 patients per study
51 site. The designated monitor will contact and visit the investigator on a regular basis and will be allowed
52 to have direct access to all source documents, which are needed to verify all CRF and eCRF entries and
53 other protocol-related documents provided that subject confidentiality is maintained in agreement with
54
55
56
57
58
59
60

1
2
3 legal regulations. It will be the monitors' responsibility to inspect the CRFs and eCRFs at regular
4 intervals according to the monitoring plan throughout the study, to verify the adherence to the protocol
5 and the completeness, consistency, and accuracy of the data being entered on them.
6
7
8
9
10

11 *Data Safety*
12

13 All hard-copy forms, such as CRFs, source data and informed consents will be stored in locked rooms
14 within a secured area and are only accessible by investigators involved in the trial.
15
16

17 Access to data is strictly controlled and will only be provided to the sponsor (Medical University of
18 Vienna), the study investigators, ethics committee (Ethic committee of the Medical University of
19 Vienna), and if requested the Austrian Competent Authorities (Bundesamt für Sicherheit im
20 Gesundheitswesen (BASG)).
21
22
23
24
25

26 Data will be stored after publishing of the trial and all of the sub-studies by Iron Mountain Austrian
27 Archivierungs GmbH (Gewerbeparkstraße 3, 2282 Markgrafneusiedl, Austria) for a period of not less
28 than twenty-five years in accordance with the Conduct of a Clinical Trial (ICH E6 Section 8) and as
29 required by the national laws.
30
31
32
33

34
35
36 *Patient and Public involvement*
37

38 No patient or public involvement.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The RAPID-II trial will provide clinical evidence regarding the effects of desflurane, sevoflurane, and propofol on postoperative delirium in older adults undergoing moderate- to high-risk major noncardiac surgery.

The most recent and largest trial in over 1200 patients demonstrated that propofol-based anaesthesia was associated with a lower incidence of postoperative delirium within the first five days as compared to sevoflurane-based anaesthesia.¹⁶ However, they further showed that the long-term cognitive function – assessed via telephone interviews – was significantly better in the sevoflurane group as compared to the propofol group three years after surgery.¹⁶ Cao et al. suggested that the choice of isoflurane or desflurane instead of sevoflurane would have led to similar results.¹⁶ Nevertheless, it has to be emphasized that this is not based on any scientific evidence.

In fact, pharmacokinetic characteristics of desflurane lead to significantly faster elimination as compared to sevoflurane.^{34–36} Desflurane has a blood/gas coefficient of 0.45, which is the lowest of all available volatile anaesthetics.³⁴ Thus, the context-sensitive decrement time of desflurane is significantly faster as compared to sevoflurane.^{35,36} Specifically, the time until 90% of sevoflurane is eliminated increases significantly after two hours of administration, while the time of elimination of 90% of desflurane remains relatively constant.^{35,36} Some studies have shown that desflurane led to significantly faster extubation times, faster eye opening to verbal command, faster reciting of full name, and faster orientation as compared to sevoflurane.^{17–21} Furthermore, a recent pilot study showed that in patients, who received desflurane for major surgery, postoperative cognitive function assessed via Mini Mental State Examination (MMSE) was significantly higher after desflurane anaesthesia as compared to sevoflurane.³⁷ Interestingly, studies investigating different anaesthetics with a clinical meaningful neurological outcome are still lacking, specifically in regards to desflurane. Thus, the strength of our trial is that it will be the first adequately powered randomised study comparing the effects of desflurane on the incidence of postoperative delirium as compared to sevoflurane or propofol.

In addition, measuring anaesthetic depth by simply using the BIS value is not sufficient. In the study by Cao et al. only 70% of patients were monitored with BIS and the BIS values and not raw EEG or colour

1
2
3 spectral density array were used for the determination of anaesthetic depth.¹⁶ It has been shown that
4 during emergence, volatile anaesthetics induce higher power in frequencies above 15 Hz compared to
5 propofol resulting in higher BIS indices for this drug group.³⁸ Specific index values do not always
6 correlate with the same clinical state of consciousness. We therefore plan to further compare colour
7 spectral density arrays between the groups.
8
9
10
11
12

13
14
15 The use of volatile anaesthetics has been criticized in recent years due to their environmental effects.^{39,40}
16 We are aware that a discontinuation of desflurane has been proposed recently.⁴¹ These recommendations
17 are often based on calculations of the global warming potential of 100 years (GWP_{100}), which should be
18 used for gases with atmospheric lifetimes of at least 100 years.⁴² However, since the atmospheric lifetime
19 of desflurane is approximately 14 years, the GWP_{100} formula is inadequate, which often leads to
20 overestimation of its global warming potential.^{42–44} Furthermore, propofol leads to CO₂ emissions and
21 water pollution, which has significant deleterious effects on global warming, which are often
22 underestimated.^{42,43,45} Therefore, it is of utmost importance to provide evidence on patient outcomes
23 before decisions with wide clinical implications will be made. The discontinuation of desflurane and the
24 choice of general anaesthetic in routine care should not be based solely on environmental reasons but
25 also should be supported by their clinical impact and evidence-based results.
26
27
28
29
30
31
32
33
34
35
36
37

38
39
40 This trial will have some limitations. Firstly, due to the different methods of administration and because
41 this is a large, multi-centre, pragmatic trial, blinding of the attending anaesthetists will not be suitable.
42 However, to provide equal depth of anaesthesia, dosage of anaesthetics will be standardized for all
43 patients with an aim of BIS values 40 to 60. Furthermore, DSA will be further analysed and compared
44 between the groups. Nevertheless, it can't be ruled out that BIS values might be different between the
45 groups, which could pose as significant confounder for postoperative delirium. Therefore, regular
46 analyses of BIS values between the groups are planned for surveillance of protocol adherence regarding
47 intraoperative BIS values at least after every 150 patients enrolled. To further limit possible bias, all
48 postoperative outcomes will only be assessed by study personnel blinded toward the randomly assigned
49 group. Secondly, we will only include patients planned for major noncardiac surgery. Furthermore, we
50
51
52
53
54
55
56
57
58
59
60

1
2
3 will only include patients ≥ 65 years of age, since the incidence of postoperative delirium is highest in
4 this patient population.² Thus, the generalisability for emergency surgery, cardiac surgery, and younger
5 patients will be limited. Lastly, some patients might be discharged from the hospital before the fifth
6 postoperative day, limiting the delirium assessments. However, based on the current clinical standard of
7 care, patients with delirium are unlikely to be discharged from hospital. Thus, the number of patients
8 with delirium missed in our outcome assessment should be minimal.

15
16
17 In summary, the RAPID-II trial will be a multi-centre, observer-blinded, prospective, randomised
18 clinical trial that is adequately powered to evaluate the effects of desflurane versus sevoflurane versus
19 propofol for maintenance of anaesthesia on the incidence of postoperative delirium in older adults
20 undergoing moderate- to high-risk major noncardiac surgery. The results of this trial might therefore
21 provide evidence regarding the effects of anaesthetics on neurologic outcomes and more importantly
22 will give clinicians guidance for the choice of general anaesthetics in highly vulnerable patients.

Trial Status

Actual protocol: Version 5.0, March 5, 2024. Patient recruitment started in September 2023.

Funding Statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The authors have no conflicts of interest.

Authors' contributions

AT, CR, EF, BK, BS: conceptualisation and study design; AT, CR, EF, AG: first draft of the manuscript; CE, KH, NA, NH, BH, OZ, DE, KMH, HL, ML, BR, SS, MS, GZ, FWZ, IE, CG, NI, MK, SR, BR, ST, MW: data collection; MF, AG: data management; AG: statistical analysis; AT, EF, BK, BS, CE, KH, NA, NH, BH, OZ, MF, AG, CR: editing and critical review of the manuscript; All authors read and approved the final manuscript. AT is the guarantor.

References

1. Humeidan ML, Reyes JPC, Mavarez-Martinez A, et al. Effect of Cognitive Prehabilitation on
2 the Incidence of Postoperative Delirium among Older Adults Undergoing Major Noncardiac
3 Surgery: The Neurobics Randomized Clinical Trial. *JAMA Surg.* 2021;156(2):148-156.
4 doi:10.1001/jamasurg.2020.4371
5. Li GH, Zhao L, Lu Y, et al. Development and validation of a risk score for predicting
6 postoperative delirium after major abdominal surgery by incorporating preoperative risk factors
7 and surgical Apgar score. *J Clin Anesth.* 2021;75(July):110408.
8 doi:10.1016/j.jclinane.2021.110408
9. Mrkobrada M, Chan MTV, Cowan D, et al. Perioperative covert stroke in patients undergoing
10 non-cardiac surgery (NeuroVISION): a prospective cohort study. *The Lancet.*
11 2019;394(10203):1022-1029. doi:10.1016/S0140-6736(19)31795-7
12. Daiello LA, Racine AM, Yun Gou R, et al. Postoperative Delirium and Postoperative
13 Cognitive Dysfunction: Overlap and Divergence. *Anesthesiology.* 2019;131(3):477-491.
14 doi:10.1097/ALN.0000000000002729
15. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. *The Lancet.*
16 2014;383(9920):911-922. doi:10.1016/S0140-6736(13)60688-1
17. Rudolph JL, Marcantonio ER. Postoperative Delirium: Acute change with long-term
18 implications. *Anesth Analg.* 2011;112(5):1202-1211. doi:10.1213/ANE.0b013e3182147f6d
19. Gleason LJ, Schmitt EM, Kosar CM, et al. Effect of delirium and other major complications on
20 outcomes after elective surgery in older adults. *JAMA Surg.* 2015;150(12):1134-1140.
21 doi:10.1001/jamasurg.2015.2606
22. Gou RY, Hsieh TT, Marcantonio ER, et al. One-Year Medicare Costs Associated with
23 Delirium in Older Patients Undergoing Major Elective Surgery. *JAMA Surg.* 2021;156(5):430-
24 442. doi:10.1001/jamasurg.2020.7260
25. Goldberg TE, Chen C, Wang Y, et al. Association of delirium with long-term cognitive
26 decline: A meta-analysis. *JAMA Neurol.* 2020;77(11):1373-1381.
27 doi:10.1001/jamaneurol.2020.2273

- 1
2
3 10. Mohanty S, Rosenthal RA, Russell MM, Neuman MD, Ko CY, Esnaola NF. Optimal
4 Perioperative Management of the Geriatric Patient: A Best Practices Guideline from the
5 American College of Surgeons NSQIP and the American Geriatrics Society. *J Am Coll Surg.*
6 2016;222(5):930-947. doi:10.1016/j.jamcollsurg.2015.12.026
- 7 11. Robinson TN, Raeburn CD, Tran Z V., Brenner LA, Moss M. Motor subtypes of postoperative
8 delirium in older adults. *Archives of Surgery.* 2011;146(3):295-300.
9 doi:10.1001/archsurg.2011.14
- 10 12. Kunicki ZJ, Ngo LH, Marcantonio ER, et al. Six-Year Cognitive Trajectory in Older Adults
11 Following Major Surgery and Delirium. *JAMA Intern Med.* 2023;183(5):442-450.
12 doi:10.1001/jamainternmed.2023.0144
- 13 13. Mei X, Zheng HL, Li C, et al. The Effects of Propofol and Sevoflurane on Postoperative
14 Delirium in Older Patients: A Randomized Clinical Trial Study. *Journal of Alzheimer's
15 Disease.* 2020;76(4):1627-1636. doi:10.3233/JAD-200322
- 16 14. Saller T, Hubig L, Seibold H, et al. Association between post-operative delirium and use of
17 volatile anesthetics in the elderly: A real-world big data approach. *J Clin Anesth.* 2022;83.
18 doi:10.1016/j.jclinane.2022.110957
- 19 15. Jiang JL, Zhang L, He LL, et al. Volatile Versus Total Intravenous Anesthesia on Postoperative
20 Delirium in Adult Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial.
21 *Anesth Analg.* 2023;136(1):60-69. doi:10.1213/ANE.0000000000006257
- 22 16. Cao SJ, Zhang Y, Zhang YX, et al. Delirium in older patients given propofol or sevoflurane
23 anaesthesia for major cancer surgery: a multicentre randomised trial. *Br J Anaesth.*
24 2023;131(2):253-265. doi:10.1016/j.bja.2023.04.024
- 25 17. Iannuzzi E, Iannuzzi M, Viola G, Cerulli A, Cirillo V, Chiefari M. Desflurane and sevoflurane
26 in elderly patients during general anesthesia: a double blind comparison. *Minerva Anestesiol.*
27 2005;71(4):147-155. http://www.ncbi.nlm.nih.gov/pubmed/15756155
- 28 18. Wang C, Li L, Xu H, Lv H, Zhang H. Effect of desflurane–remifentanil or sevoflurane–
29 remifentanil on early recovery in elderly patients: A meta-analysis of randomized controlled
30 trials. *Pharmazie.* 2019;74(4):201-205. doi:10.1691/ph.2019.8935

- 1
2
3 19. Yu H, Zhang L, Ma Y, Yu H. Early postoperative recovery in operating room after desflurane
4 anesthesia combined with Bispectral index (BIS) monitoring and warming in lengthy
5 abdominal surgery: A randomized controlled study. *BMC Anesthesiol.* 2018;18(1):1-7.
6
7 doi:10.1186/s12871-018-0577-6
8
9 20. Heavner JE, Kaye AD, Lin BK, King T. Recovery of elderly patients from two or more hours
10 of desflurane or sevoflurane anaesthesia. *Br J Anaesth.* 2003;91(4):502-506.
11
12 doi:10.1093/bja/aeg221
13
14 21. De Oliveira GS, Fitzgerald PC, Ahmad S, Jay Marcus R, McCarthy RJ. Desflurane/fentanyl
15 compared with sevoflurane/fentanyl on awakening and quality of recovery in outpatient
16 surgery using a Laryngeal Mask Airway: A randomized, double-blinded controlled trial. *J Clin*
17 *Anesth.* 2013;25(8):651-658. doi:10.1016/j.jclinane.2013.07.006
18
19 22. Taschner A, Fleischmann E, Horvath K, et al. Desflurane versus sevoflurane anesthesia and
20 postoperative recovery in older adults undergoing minor- to moderate-risk noncardiac surgery
21 – A prospective, randomized, observer-blinded, clinical trial. *J Clin Anesth.* 2024;98:111576.
22
23 doi:10.1016/j.jclinane.2024.111576
24
25 23. Hamadnalla H, Sessler DI, Troianos CA, et al. Optimal interval and duration of CAM-ICU
26 assessments for delirium detection after cardiac surgery. *J Clin Anesth.*
27
28 2021;71(March):110233. doi:10.1016/j.jclinane.2021.110233
29
30 24. Marcantonio ER, Ngo LH, Connor MO, et al. 3D-CAM: Derivation and Validation of a 3-
31 Minute Diagnostic Interview for CAM-defined Delirium. *Ann Intern Med.* 2014;161(8):554-
32 561. doi:10.7326/M14-0865.3D-CAM
33
34 25. Evers LA, Silbert BS. Postoperative cognitive dysfunction and noncardiac surgery. *Anesth*
35 *Analg.* 2018;127(2):496-505. doi:10.1213/ANE.0000000000003514
36
37 26. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction
38 in the elderly: ISPOCD1 study. *Lancet.* 1998;351(9106):857-861. doi:10.1016/S0140-
39 6736(97)07382-0
40
41 27. Krishnan K, Rossetti H, Hynan LS, et al. Changes in Montreal Cognitive Assessment Scores
42 Over Time. *Assessment.* 2017;24(6):772-777. doi:10.1177/1073191116654217
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28. Tan HH, Xu J, Teoh HL, et al. Decline in changing montreal cognitive assessment (MoCA)
4 scores is associated withpost-stroke cognitive decline determined by a formal
5 neuropsychological evaluation. *PLoS One*. 2017;12(3). doi:10.1371/journal.pone.0173291
6
7 29. Pendlebury ST, Welch SJ V, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone
8 assessment of cognition after TIA and stroke : TICSm and telephone MoCA vs face-to-face
9 MoCA and neuropsychological battery. *Stroke*. 2013;44(1):227-229.
10
11 15 doi:10.1161/STROKEAHA.112.673384.Telphone
12
13 16
14 17 30. Zietemann V, Kopczak A, Müller C, Wollenweber FA, Dichgans M. Validation of the
15 telephone interview of cognitive status and telephone montreal cognitive assessment against
16 detailed cognitive testing and clinical diagnosis of mild cognitive impairment after stroke.
17
18 24 *Stroke*. 2017;48(11):2952-2957. doi:10.1161/STROKEAHA.117.017519
19
20 25
21 26 31. Takeuchi M, Takeuchi H, Fujisawa D, et al. Incidence and risk factors of postoperative
27 delirium in patients with esophageal cancer. *Ann Surg Oncol*. 2012;19(12):3963-3970.
28
29 32 doi:10.1245/s10434-012-2432-1
30
31 33 32. Robinson TN, Raeburn CD, Tran Z V., Angles EM, Brenner LA, Moss M. Postoperative
34 delirium in the elderly: Risk factors and outcomes. *Ann Surg*. 2009;249(1):173-178.
35
36 37 doi:10.1097/SLA.0b013e31818e4776
38
39 33. Wildes TS, Mickle AM, Abdallah A Ben, et al. Effect of electroencephalography-guided
40 anesthetic administration on postoperative delirium among older adults undergoing major
41 surgery the engages randomized clinical trial. *JAMA - Journal of the American Medical
42 Association*. 2019;321(5):473-483. doi:10.1001/jama.2018.22005
43
44 47 34. Wissing H, Kuhn I, Rietbrock S, Fuhr U. *Pharmacokinetics of Inhaled Anaesthetics in a
48 Clinical Setting: Comparison of Desflurane, Isoflurane and Sevoflurane* †. Vol 84.; 2000.
49
50 51 35. Lockwood G. Theoretical context-sensitive elimination times for inhalation anaesthetics. *Br J
52 Anaesth*. 2010;104(5):648-655. doi:10.1093/bja/aeq051
53
54 55 36. Bailey JM. Context-Sensitive Half-Times and Other Decrement Times of Inhaled Anesthetics.
56 *Anesth Analg*. 1997;85:681-686.
57
58
59
60

- 1
2
3 37. Tachibana S, Hayase T, Osuda M, Kazuma S, Yamakage M. Recovery of postoperative
4 cognitive function in elderly patients after a long duration of desflurane anesthesia: a pilot
5 study. *J Anesth.* 2015;29(4):627-630. doi:10.1007/s00540-015-1979-y
6
7 38. Lipp M, Schneider G, Kreuzer M, Pilge S. Substance-dependent EEG during recovery from
8 anesthesia and optimization of monitoring. *J Clin Monit Comput.* 2024;38(3):603-612.
9 doi:10.1007/s10877-023-01103-4
10
11 39. White SM, Shelton CL. Abandoning inhalational anaesthesia. *Anaesthesia.* 2020;75(4):451-
12 454. doi:10.1111/anae.14853
13
14 40. Ryan SM, Nielsen CJ. Global warming potential of inhaled anesthetics: Application to clinical
15 use. *Anesth Analg.* 2010;111(1):92-98. doi:10.1213/ANE.0b013e3181e058d7
16
17 41. Van Norman GA, Jackson S. The anesthesiologist and global climate change: an ethical
18 obligation to act. *Curr Opin Anaesthesiol.* 2020;33(4):577-583.
19 doi:10.1097/ACO.0000000000000887
20
21 42. Slingo JM, Slingo ME. The science of climate change and the effect of anaesthetic gas
22 emissions. *Anaesthesia.* Published online 2024. doi:10.1111/anae.16189
23
24 43. Tapley P, Patel M, Slingo M. Abandoning inhalational anaesthesia. *Anaesthesia.*
25 2020;75(9):1257-1258. doi:10.1111/anae.15142
26
27 44. Pierrehumbert RT. Short-lived climate pollution. *Annu Rev Earth Planet Sci.* 2014;42:341-379.
28 doi:10.1146/annurev-earth-060313-054843
29
30 45. Kostrubiak M, Vatovec CM, Dupigny-Giroux LA, et al. Water Pollution and Environmental
31 Concerns in Anesthesiology. *J Med Syst.* 2020;44(9):169. doi:10.1007/s10916-020-01634-
32 2/Published
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Captions for Figures**
4
5
6
7
8


9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study procedure

For peer review only

Enseignement Supérieur (ABES) :
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figure 1. Study procedure



BIS, bispectral index; ICU, intensive care unit.

1
2
3
4
5
6
7
8
9
10
11
12 **Supplementary Online Content**

13
14 **eAppendix 1.** List of investigators RAPID II Trial

15
16 **eAppendix 2.** Definition of moderate- to high-risk major noncardiac surgery

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 This supplementary material has been provided by the authors to give readers additional information
57
58 about their work.
59
60

eAppendix 1. List of investigators RAPID II Trial

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Medical University of Vienna: Nikolas Adamowitsch; David Emler; Edith Fleischmann; Melanie Fraunschiel; Alexandra Graf; Nicole Hantakova; Beatrix Hochreiter; Kira Margarete Hörl; Katharina Horvath; Barbara Kabon; Helena Langthaler; Magdalena List; Christian Reiterer; Barbara Rossi; Simon Schallmeiner; Mathias Stiefsohn; Alexander Taschner; Giulia Zanvettor; Florian Wolfgang Zenz; Oliver Zotti;
2. Medical University of Innsbruck: Christine Eckhardt; Iris Emshoff; Christoph Geiger; Nicole Innerhofer; Mario Kofler; Sasa Rajsic; Beatrix Reyer; Barbara Sinner; Susanne Trübsbach; Melanie Widmann;

eAppendix 2. Definition of moderate- to high-risk major noncardiac surgery

We defined the following surgeries to meet the criteria for moderate- to high-risk major noncardiac surgery:

- Major general surgery: complex visceral resection, partial or total colectomy, gastrectomy, partial liver resection, pancreas resection, oesophageal resection, anterior rectal resection, retroperitoneal tumour resection, small bowel resection
- Major urologic surgery: prostatectomy, cystectomy, nephrectomy, retroperitoneal tumour resection, major open lymphadenectomy
- Major gynaecologic surgery: retroperitoneal tumour resection, exenteration, cytoreduction surgery, open hysterectomy
- Major orthopaedic surgery: total hip replacement, partial hip replacement, total knee replacement

1
2
3
4
5
6
7 **PatientInneninformation¹ und Einwilligungserklärung**
8 **zur Teilnahme an der klinischen Studie**

9
10
11
12
13 **Einfluss von Desfluran versus Sevofluran versus Propofol auf das Auftreten von Delir bei älteren**
14 **PatientInnen, die sich einer nicht-herzchirurgischen Operation mit mittelgroßem oder großem**
15 **Risiko unterziehen**

16
17
18 **Eine prospektive, verblindete, randomisierte, klinische Studie**

19
20
21 The effect of DesfluRane versus SevoflurAne versus Propofol on postoperative Delirium in elderly patients
22 undergoing moderate- to high-risk abdominal surgery – a prospective observer-blinded, randomized, clinical trial

23
24
25 **RAPID-II Trial**

26
27 Sehr geehrte Teilnehmerin, sehr geehrter Teilnehmer!

28
29 Wir laden Sie ein an der oben genannten klinischen Studie teilzunehmen. Die Aufklärung darüber erfolgt in einem
30 ausführlichen ärztlichen Gespräch.

31
32 **Ihre Teilnahme an dieser klinischen Studie erfolgt freiwillig. Sie können jederzeit ohne Angabe von Gründen**
33 **aus der Studie ausscheiden. Die Ablehnung der Teilnahme oder ein vorzeitiges Ausscheiden aus dieser Studie**
34 **hat keine nachteiligen Folgen für Ihre medizinische Betreuung.**

35
36 Klinische Studien sind notwendig, um verlässliche neue medizinische Forschungsergebnisse zu gewinnen.
37 Unverzichtbare Voraussetzung für die Durchführung einer klinischen Studie ist jedoch, dass Sie Ihr Einverständnis zur
38 Teilnahme an dieser klinischen Studie schriftlich erklären. Bitte lesen Sie den folgenden Text als Ergänzung zum
39 Informationsgespräch mit Ihrem Arzt sorgfältig durch und zögern Sie nicht Fragen zu stellen.

40
41 Bitte unterschreiben Sie die Einwilligungserklärung nur

- 42
43 - wenn Sie Art und Ablauf der klinischen Studie vollständig verstanden haben,

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 ¹ Wegen der besseren Lesbarkeit wird im weiteren Text zum Teil auf die gleichzeitige Verwendung weiblicher
und männlicher Personenbegriffe verzichtet. Gemeint und angesprochen sind – sofern zutreffend – immer
beide Geschlechter.

- wenn Sie bereit sind, der Teilnahme zuzustimmen und
- wenn Sie sich über Ihre Rechte als Teilnehmer an dieser klinischen Studie im Klaren sind.

Zu dieser klinischen Studie, sowie zur Patienteninformation und Einwilligungserklärung wurde von der zuständigen Ethikkommission eine befürwortende Stellungnahme abgegeben.

16 1. Was ist der Zweck der klinischen Studie? 17

18 Der Sponsor dieser Studie ist: *Medizinische Universität Wien*. Der Sponsor ist für die Verfassung und für die
19 ordnungsgemäße Durchführung der Studie verantwortlich.
20

21 Ältere Patienten haben nach größeren nicht-herzchirurgischen Operationen ein erhöhtes Risiko nach einer
22 Operation ein Delir zu entwickeln. Unter Delir nach Operationen versteht man einen kurzfristigen
23 Verwirrtheitszustand, der bis zu mehreren Tagen anhalten kann. Darüber hinaus haben Studien gezeigt, dass Delir
24 nach Operationen auch langfristig die neurokognitive Funktion, das heißt die Denkleistung, beeinträchtigen kann.
25 Zusätzlich ist ein Delir nach Operationen auch mit einem verzögerten Erholungsverlauf nach der Operation
26 vergesellschaftet. Interessanterweise gibt es bis jetzt keine eindeutigen Studien, welche vorbeugende
27 Gegenmaßnahmen zur Entstehung von Delir beweisen konnten. Aus diesem Grund untersuchen wir in der
28 vorliegenden Studie, ob möglicherweise die Wahl des Narkosemittels einen Einfluss auf die Entstehung von Delir
29 haben könnte.
30

31 Für die Aufrechterhaltung von Narkosen während einer Operation werden üblicherweise Narkosegase, wie zum
32 Beispiel Desfluran oder Sevofluran, bzw. ein flüssiges Narkosemittel, wie zum Beispiel Propofol verwendet. Alle
33 diese Narkosemittel werden routinemäßig im klinischen Betrieb eingesetzt. Daten bezüglich eines möglichen
34 Vorteils eines dieser Narkosemittel bezugnehmend auf das Auftreten von Delir nach Operationen liegen bis dato
35 noch nicht vor. Alle diese Narkosemittel haben einen ähnlichen Wirkmechanismus, unterscheiden sich jedoch an
36 der Geschwindigkeit, welche das Narkosemittel braucht, um wieder aus dem Körper ausgeschieden zu werden.
37 Das führt dazu, dass auch die Wirkdauer der Narkosemittel unterschiedlich ist. Daher nehmen wir an, dass das
38 Narkosemittel mit der kürzesten Wirkdauer einen positiven Effekt, im Speziellen den größten vorbeugenden Effekt
39 auf die Entstehung von Delir nach Operationen hat, verglichen mit den länger-wirkenden Narkosemitteln.
40 Ziel dieser Studie ist es, herauszufinden, ob durch die Gabe von den oben genannten drei unterschiedlichen
41 Narkosemedikamenten (Desfluran, Sevofluran, Propofol) zur Narkoseaufrechterhaltung während Ihrer Operation
42 ein verringertes Auftreten von Delir nach Operationen erzielt werden kann.
43

55 2. Welche anderen Behandlungsmöglichkeiten gibt es? 56

57 Zur Aufrechterhaltung Ihrer Narkose werden derzeit routinemäßig Desfluran, Sevofluran und Propofol im
58 klinischen Alltag verwendet. An unserer Klinik werden keine anderen Narkosemittel für die Aufrechterhaltung
59 verwendet.
60

der Narkose während einer Operation routinemäßig verwendet. Derzeit gibt es keinen festgelegten klinischen Standard, welches Narkosemedikament zu verwenden ist. Die jeweilige Wahl des Narkosemedikaments für die Operation richtet sich demnach ausschließlich nach dem Ermessen des behandelnden Arztes.

3. Wie läuft die klinische Prüfung ab?

Diese klinische Prüfung wird an der Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie der Medizinischen Universität Wien, der Universitätsklinik für Anästhesiologie und Intensivmedizin der Medizinischen Universität Graz und der Universitätsklinik für Anästhesie und Intensivmedizin der Medizinischen Universität Innsbruck durchgeführt, und es werden insgesamt 1332 Patienten daran teilnehmen.

Ihre Teilnahme an dieser klinischen Prüfung wird am Tag vor Ihrer Operation beginnen. Bei Teilnahme an dieser klinischen Prüfung wird die Narkose wie üblich mit einem Narkosemittel und einem Schmerzmittel über die Vene eingeleitet. Für die Dauer der Operation werden Sie zur Beatmung einen Beatmungsschlauch erhalten. Erst nachdem Sie bereits in Vollnarkose sind, wird dieser von Ihrem Narkosearzt vorsichtig eingeführt. Danach wird das Narkosegas über die Atemluft zugeführt oder das Narkosemittel über die Vene durchgehend für die Aufrechterhaltung Ihrer Narkose verabreicht. Während der gesamten Operation wird die Tiefe Ihrer Narkose anhand eines Monitors genau überwacht und gesteuert. Sobald die Operation beendet ist, wird die Zufuhr des Narkosemedikamentes beendet. Nachdem Sie wieder selbstständig atmen und Sie kontaktierbar sind, wird – wie derzeitiger klinischer Standard – der Beatmungsschlauch wieder entfernt und Sie werden zur weiteren Überwachung in den Aufwachraum oder die Intensivstation transferiert. Im Aufwachraum und Intensivstation werden Ihr Blutdruck, Ihre Herzfrequenz und Ihre Sauerstoffsättigung durchgehend überwacht und aufgezeichnet. Ebenso werden Sie nach Übelkeit, Stärke der Schmerzen, mögliche Einschränkungen Ihrer Atmung gefragt. In den ersten fünf Tagen nach der Operation wird ein Studienmitarbeiter Sie zweimal täglich auf der Intensivstation oder Normalstation besuchen und einen Fragebogen zur Erhebung eines eventuellen Verwirrtheitszustandes mit Ihnen durchgehen, der circa 5 bis 10 Minuten in Anspruch nimmt.

Insgesamt umfasst die Teilnahme an dieser klinischen Prüfung den Zeitraum von dem Tag vor der Operation bis ein Jahr nach der Operation. 30 Tage und ein Jahr nach der Operation werden Sie von einem Studienmitarbeiter telefonisch kontaktiert und nach Ihrem Gesundheitszustand befragt. Bei der telefonischen Befragung wird außerdem ein Mitarbeiter von uns einen Fragebogen mit insgesamt 9 Fragen zur Feststellung Ihrer Denkleistung mit Ihnen durchführen. Das Telefongespräch wird ungefähr 5 bis 10 Minuten in Anspruch nehmen.

Diese Studie wird **randomisiert** und **verblindet** durchgeführt.

Randomisiert bedeutet, dass Sie am Tag Ihrer Operation per Zufallsprinzip einer der drei Gruppen zugewiesen werden.

Verblindet bedeutet, dass Sie nicht wissen, ob Sie Desfluran, Sevofluran oder Propofol erhalten. Ebenso weiß der Untersucher auf der Intensivstation und auf der Normalstation nicht, ob Sie Desfluran, Sevofluran oder Propofol erhalten haben.

6 Am Tag der Operation werden Sie mittels Zufallsgenerator einer der folgenden Gruppen zugeteilt:

7
8 **Gruppe 1 (Desfluran):** Nach Einleitung der Narkose wird Desfluran zur Aufrechterhaltung der Narkose während der
9 gesamten Operation verwendet.

10
11 **Gruppe 2 (Sevofluran):** Nach Einleitung der Narkose wird Sevofluran zur Aufrechterhaltung der Narkose während der
12 gesamten Operation verwendet.

13
14 **Gruppe 3 (Propofol):** Nach Einleitung der Narkose wird Propofol zur Aufrechterhaltung der Narkose während der
15 gesamten Operation verwendet.

16
17 Bei Teilnahme an dieser Studie kommt es zu keiner Veränderung Ihrer klinischen Behandlung, es werden
18 ausschließlich die unterschiedlichen Eigenschaften der oben genannten Narkosemedikamente auf das Auftreten von
19 Delir untersucht.

20
21 Substudie I – Nierenfunktion: Im Rahmen dieser Substudie wird im Zuge der Studien-spezifischen Blutabnahmen eine
22 zusätzliche Bestimmung der Nierenfunktion durchgeführt.

23
24 Substudie II – Neue Laborparameter zur Bestimmung der möglichen Schädigung von Nervenzellen: Im Rahmen dieser
25 Substudie wird im Zuge der Studien-spezifischen Blutabnahmen weitere Laborwerte bestimmt, und zwar zur Messung
26 einer möglichen Schädigung von Nervenzellen. Dafür werden vor der Operation und am zweiten Tag nach der
27 Operation 4 Röhrchen mit insgesamt circa 50mL Blut entnommen. Folgende Biomarker geben Auskunft über
28 Nervenschaden und werden im Rahmen dieser Substudie bestimmt: NFL, GFAP, HMGB1, MANF.

29
30
31
32
33
34
35
36
37
38 Folgende Maßnahmen werden ausschließlich aus Studiengründen durchgeführt:

39
40
41 **a) Montreal Cognitive Assessment (MoCA):** Hierbei handelt es sich um einen Fragebogen, welcher zur Erfassung
42 Ihrer Denkleistung dient. Dafür wird ein Studienmitarbeiter am Tag vor Ihrer Operation einen Fragebogen mit Ihnen
43 durchführen. Dies wird ca. 5 bis 10 Minuten Ihrer Zeit in Anspruch nehmen. 30 Tage sowie ein Jahr nach Ihrer
44 Operation werden Sie telefonisch von einem unserer Studienmitarbeiter kontaktiert. Im Rahmen dieses Telefonats wird
45 nochmals der Fragebogen, welcher auch vor der Operation verwendet wurde, um Ihre Denkleistung zu ermitteln,
46 durchgeführt. Dies wird erneut ca. 5 bis 10 Minuten Ihrer Zeit in Anspruch nehmen.

47
48
49
50
51 **b) 3D-Cognitive Assessment Method (3D-CAM):** Hierbei handelt es sich um ein Testinstrument, welches den
52 Verwirrheitszustand nach Operationen beurteilen soll. In der Früh und am Abend in den ersten fünf Tagen nach der
53 Operation wird ein Studienmitarbeiter Sie auf der Intensivstation oder Bettenstation besuchen und einen Fragebogen
54 mit Ihnen durchgehen. Ein Studienmitarbeiter wird Ihnen insgesamt 10 Fragen stellen. Außerdem wird erhoben, ob
55 Ihnen seit der Operation übel war oder ob sie erbrechen mussten. Diese Fragen werden jeweils ca. 5-10 Minuten Ihrer
56 Zeit in Anspruch nehmen.

c) **Digit Symbol Substitution Test (DSST):** Hierbei handelt es sich um ein Testinstrument, das Hinweise auf das Vorhandensein einer möglichen Hirnfunktionsstörung oder auch Demenz gibt. Im Rahmen dieses Tests müssen Sie Ziffern- und Symbolkombinationen so schnell wie möglich miteinander verbinden. Dieser Test wird am Tag vor Ihrer Operation und am fünften Tag nach Ihrer Operation durchgeführt und nimmt jeweils ungefähr 5 bis 10 Minuten Ihrer Zeit in Anspruch.

d) **Trail Making Tests (Teil A, Teil B):** Dieser Test kann einen Hinweis auf eine mögliche Hirnfunktionsstörung geben und besteht aus zwei Teilen. Bei Teil A müssen Sie Ziffern in aufsteigender Reihenfolge so schnell wie möglich miteinander verbinden. Bei Teil B müssen Sie Ziffern und Buchstaben in aufsteigender Reihenfolge so schnell wie möglich miteinander verbinden. Dieser Test wird am Tag vor Ihrer Operation und am fünften Tag nach Ihrer Operation durchgeführt und nimmt jeweils ungefähr 5 bis 10 Minuten Ihrer Zeit in Anspruch.

Während dieser klinischen Studie werden folgende Blutabnahmen durchgeführt: vor Beginn der Operation wird eine Blutabnahme zur Bestimmung der Herzenzyme, Nierenfunktion, Entzündungswerte und Laborparamater spezifisch für die Gehirnzellfunktion, um die Ausgangswerte zu bestimmen, durchgeführt (3 Röhrchen mit max. 15 ml Blut). Innerhalb der ersten zwei Stunden nach Operationsende sowie am zweiten Tag nach der Operation werden die Herzenzyme, Nierenfunktionswerte, Entzündungswerte und Laborparamater spezifisch für die Gehirnzellfunktion erneut bestimmt (3 Röhrchen mit max. 15 ml Blut). Die im Rahmen dieser Studie durchgeführten Blutabnahmen werden, wenn möglich über einen liegenden Katheter durchgeführt. Sollte kein liegender Katheter vorhanden sein, wird Ihnen Blut über eine Vene durch einen Stich abgenommen. Für diese Studie gilt, dass die gewonnenen Blutproben auch nach den Analysen aufbewahrt werden und gegebenenfalls zukünftige Analysen durchgeführt werden. Ihre Blutproben werden an dem jeweiligen Studienzentrum bei -80°C aufbewahrt: Medizinische Universität Wien, Univ. Klinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Spitalgasse 23, 1090 Wien (verantwortlicher Prüfarzt: PD Dr. Christian Reiterer, PhD; Medizinische Universität Graz, Univ. Klinik für Anästhesiologie und Intensivmedizin, Auenbruggerplatz 5/5, 8036 Graz (verantwortlicher Prüfarzt: Dr. Michael Eichlseder); Medizinische Universität Innsbruck, Univ. Klinik für Anästhesie und Intensivmedizin, Anichstrasse 35, 6020 Innsbruck (verantwortliche Prüfärztin: Dr. Christine Eckhardt, PhD). Etwaige Analysen werden erst nach Vorliegen einer neuerlichen projektbezogenen befürwortenden Stellungnahme der Ethikkommission durchgeführt. Eine Weitergabe an Dritte erfolgt dabei nicht.

Während dieser klinischen Studie werden im Rahmen ihres Aufenthalts im Krankenhaus Informationen zu ihrem Genesungsverlauf nach Ihrer Operation gesammelt. Zu diesem Zweck wird Einsicht in ihre medizinischen Befunde genommen und Informationen über ihre Behandlung eingeholt.

4. Was ist Desfluran bzw. Sevofluran bzw. Propofol?

5 Desfluran ist ein routinemäßig eingesetztes Narkosegas, das zur Aufrechterhaltung von Narkosen verwendet wird. Es
6 handelt sich dabei um ein klares flüssiges Medikament, das mit Hilfe eines Verdampfers verdampft wird und das
7 resultierende Gas wird über die Narkosemaschine kontrolliert in Ihre Atemluft abgegeben. Die Aufnahme erfolgt über
8 die Lunge. Der Vorteil von Desfluran im Vergleich zu anderen Narkosegasen ist eine besonders geringe Löslichkeit
9 im Blut, was dazu führt, dass es zu einer guten Steuerbarkeit während der Operation, und zu einem schnelleren
10 Erwachen nach Beendigung der Narkosegas-Zufuhr kommt.
11
12

13 Sevofluran ist ein routinemäßig eingesetztes Narkosegas, das zur Aufrechterhaltung der Narkose verwendet wird. Es
14 handelt sich dabei um ein klares flüssiges Medikament, das mit Hilfe eines Verdampfers verdampft wird und das
15 resultierende Gas wird über die Narkosemaschine kontrolliert in Ihre Atemluft abgegeben. Die Aufnahme erfolgt über
16 die Lunge. Im Vergleich zu Desfluran ist Sevofluran löslicher im Blut, was Ihre Aufwachzeit verlängern könnte.
17
18

19 Propofol ist ein routinemäßig eingesetztes Narkosemedikament, das zur Einleitung sowie zur Aufrechterhaltung der
20 Narkose verwendet wird. Es handelt sich hierbei um ein flüssiges Medikament, welches für die Aufrechterhaltung der
21 Narkose durchgehend während der Operation über ein Blutgefäß verabreicht wird. Aufgrund des raschen
22 Wirkungseintritts und der relativ geringen Anreicherung im Körper ist Propofol während der Operation gut steuerbar.
23
24

30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 5. Worin liegt der Nutzen einer Teilnahme an der Klinischen Studie?

Mit der Anwendung eines der drei Narkosemittel kann möglicherweise das Auftreten von Delir nach der Operation verhindert werden und daher im Weiteren eine mögliche Einschränkung der Denkleistung verhindert werden. Es ist jedoch auch möglich, dass Sie durch Ihre Teilnahme an dieser klinischen Prüfung keinen direkten Nutzen für Ihre Gesundheit ziehen.

Die Ergebnisse dieser klinischen Prüfung sollen dazu beitragen, dass für andere Patienten, die dieselben geplanten Operation erhalten wie Sie, eine Verbesserung der Behandlungsmöglichkeiten während und nach Operationen gefunden wird.

48 49 50 51 52 53 54 55 56 57 58 59 60 6. Gibt es Risiken, Beschwerden und Begleiterscheinungen?

Die Verwendung von Desfluran kann zu Nebenwirkungen oder Beschwerden führen. Unerwünschte Ereignisse, die möglicherweise auf die Verabreichung von Desfluran zurückzuführen sind, sind mit der Häufigkeit angegeben und zwar sehr häufig (von bis zu 0-1 von 10), häufig (zwischen 1 von 100 und 0-1 von 10): Übelkeit oder Erbrechen (sehr häufig), Husten (sehr häufig), Rachenentzündung (häufig), Anhalten des Atems (häufig), Kopfschmerzen (häufig), Bindegautentzündung (häufig), Herzstolpern (häufig), verminderte Herzfrequenz (häufig), erhöhte Herzfrequenz (häufig), erhöhter Blutdruck (häufig), vermehrter Speichelfluss (häufig). Wie bei jeder Substanz können auch bei Anwendung von Desfluran neue, bisher unbekannte Nebenwirkungen auftreten.

Die Verwendung von Sevofluran kann zu Nebenwirkungen oder Beschwerden führen. Unerwünschte Ereignisse, die möglicherweise auf die Verabreichung von Sevofluran zurückzuführen sind, sind mit der Häufigkeit angegeben und zwar sehr häufig (von bis zu 0-1 von 10), häufig (zwischen 1 von 100 und 0-1 von 10): Aufgeregtheit (sehr häufig), verminderte Herzfrequenz (sehr häufig), verminderter Blutdruck (sehr häufig), Übelkeit oder Erbrechen (sehr häufig), Husten (sehr häufig), Benommenheit (häufig), erhöhte Herzfrequenz (häufig), erhöhter Blutdruck (häufig), verkrampte Stimmbänder (häufig), vermehrter Speichelfluss (häufig), Temperaturabfall (häufig). Wie bei jeder Substanz können auch bei Anwendung von Sevofluran neue, bisher unbekannte Nebenwirkungen auftreten.

Die Verwendung von Propofol kann zu Nebenwirkungen oder Beschwerden führen. Unerwünschte Ereignisse, die möglicherweise auf die Verabreichung von Propofol zurückzuführen sind, sind mit der Häufigkeit angegeben und zwar sehr häufig (von bis zu 0-1 von 10), häufig (zwischen 1 von 100 und 0-1 von 10): Kopfschmerzen während der Aufwachphase (häufig), verminderte Herzfrequenz (sehr häufig), verminderter Blutdruck (sehr häufig), Husten während der Einleitung der Narkose (häufig), Übelkeit oder Erbrechen während der Aufwachphase (sehr häufig), lokalisierte Schmerzen während der Einleitung der Narkose (sehr häufig).

Die im Rahmen dieser Studie durchgeführten Blutabnahmen werden, wenn möglich über einen liegenden Katheter durchgeführt. Sollte kein liegender Katheter vorhanden sein, wird Ihnen Blut über eine Vene durch einen Stich abgenommen. Dies kann zu Schmerzen an der Einstichstelle, Schwindel, Ohnmacht, Blutergüssen, Infektionen an der Einstichstelle führen.

7. Hat die Teilnahme an der klinischen Studie sonstige Auswirkungen auf die Lebensführung und welche Verpflichtungen ergeben sich daraus?

Es ergeben sich keine zusätzlichen Verpflichtungen.

8. Was ist zu tun beim Auftreten von Symptomen, Begleiterscheinungen und/oder Verletzungen?

Sollten im Verlauf der klinischen Studie irgendwelche Symptome, Begleiterscheinungen oder Verletzungen auftreten, müssen Sie diese Ihrem Arzt mitteilen, bei schwerwiegenden Begleiterscheinungen umgehend, ggf. telefonisch (Telefonnummern, etc. siehe unten).

9. Versicherung

10 Als Teilnehmer an dieser klinischen Prüfung besteht für Sie der gesetzlich vorgeschriebene verschuldensunabhängige
11 Versicherungsschutz (Personalschadenversicherung gemäß § 40 Arzneimittelgesetz, der alle Schäden abdeckt, die an
12 Ihrem Leben oder Ihrer Gesundheit durch die an Ihnen durchgeführten Maßnahmen der klinischen Prüfung verursacht
13 werden können, mit Ausnahme von Schäden auf Grund von Veränderungen des Erbmaterials in Zellen der Keimbahn.

14 Die Versicherung wurde für Sie bei der Zürich Versicherung-Aktiengesellschaft (Leopold-Ungar-Platz 2, 1190
15 Wien, Österreich; Tel.: 0800 080 80 80) unter der Polizzennummer 07229622-2 abgeschlossen. Auf Wunsch
16 können Sie in der Versicherungsunterlagen Einsicht nehmen.

17 Im Schadensfall können Sie sich direkt an den Versicherer wenden und Ihre Ansprüche selbstständig geltend
18 machen. Für den Versicherungsvertrag ist österreichisches Recht anwendbar, die Versicherungsansprüche sind in
19 Österreich einklagbar.

20 Zur Unterstützung können Sie sich auch an die Patientenanwaltschaft, Patientenvertretung oder
21 Patientenombudsschaft wenden.

22 Um den Versicherungsschutz nicht zu gefährden:

- 23
- 24 - dürfen Sie sich während der Dauer der klinischen Prüfung einer anderen medizinischen Behandlung nur
25 im Einvernehmen mit Ihrem behandelnden Prüfarzt unterziehen (**ausgenommen davon sind Notfälle**).
26 Dies gilt auch für die zusätzliche Einnahme von Medikamenten oder die Teilnahme an einer anderen
27 Studie.
 - 28 - müssen Sie dem behandelnden Prüfarzt – oder der oben genannten Versicherungsgesellschaft – eine
29 Gesundheitsschädigung, die als Folge der klinischen Prüfung eingetreten sein könnte, unverzüglich
30 mitteilen.
 - 31 - müssen Sie alles Zumutbare tun um Ursache, Hergang und Folgen des Versicherungsfalles aufzuklären
32 und den entstandenen Schaden gering zu halten. Dazu gehört ggf. auch, dass Sie Ihre behandelnden Ärzte
33 ermächtigen, vom Versicherer geforderte Auskünfte zu erteilen.

46 10. Wann wird die klinische Studie vorzeitig beendet?

47 Sie können jederzeit auch ohne Angabe von Gründen, Ihre Teilnahmebereitschaft widerrufen und aus der klinischen
48 Studie ausscheiden, ohne dass Ihnen dadurch irgendwelche Nachteile für Ihre weitere medizinische Betreuung
49 entstehen.

50 Ihr Prüfarzt wird Sie über alle neuen Erkenntnisse, die in Bezug auf diese klinische Studie bekannt werden, und für Sie
51 wesentlich werden könnten, umgehend informieren. Auf dieser Basis können Sie dann Ihre Entscheidung zur **weiteren**
52 Teilnahme an dieser klinischen Studie neu überdenken.

Es ist aber auch möglich, dass Ihr Prüfarzt entscheidet, Ihre Teilnahme an der klinischen Studie vorzeitig zu beenden, ohne vorher Ihr Einverständnis einzuholen. Die Gründe hierfür können sein:

- a) Sie können den Erfordernissen der klinischen Prüfung nicht entsprechen;
- b) Ihr Prüfarzt hat den Eindruck, dass eine weitere Teilnahme an der klinischen Prüfung nicht in Ihrem Interesse ist.

11. Datenschutz

Im Rahmen dieser klinischen Studie werden Daten über Sie erhoben und verarbeitet. Es ist grundsätzlich zu unterscheiden zwischen

- 1) jenen personenbezogenen Daten, anhand derer eine Person direkt identifizierbar ist (z.B. Name, Geburtsdatum, Adresse, Sozialversicherungsnummer, Bildaufnahmen...),
- 2) pseudonymisierten personenbezogenen Daten, das sind Daten, bei denen alle Informationen, die direkte Rückschlüsse auf die konkrete Person zulassen, entweder entfernt, durch einen Code (z. B. eine Zahl) ersetzt oder (z.B. im Fall von Bildaufnahmen) unkenntlich gemacht werden. Es kann jedoch trotz Einhaltung dieser Maßnahmen nicht vollkommen ausgeschlossen werden, dass es unzulässigerweise zu einer Re-Identifizierung kommt.
- 3) anonymisierten Daten, bei denen eine Rückführung auf die konkrete Person ausgeschlossen werden kann.

Zugang zu den Daten, anhand derer Sie direkt identifizierbar sind (siehe Punkt 1), haben der Prüfarzt und andere Mitarbeiter des Studienzentrums, die an der klinischen Studie oder Ihrer medizinischen Versorgung mitwirken. Zusätzlich können autorisierte und zur Verschwiegenheit verpflichtete Beauftragte des Sponsors Medizinische Universität Wien sowie Beauftragte von in- und/ oder ausländischen Gesundheitsbehörden und jeweils zuständige Ethikkommissionen in diese Daten Einsicht nehmen, soweit dies für die Überprüfung der ordnungsgemäßen Durchführung der klinischen Studie notwendig bzw. vorgeschrieben ist. Sämtliche Personen, die Zugang zu diesen Daten erhalten, unterliegen im Umgang mit den Daten den jeweils geltenden nationalen Datenschutzbestimmungen und/oder der EU-Datenschutz-Grundverordnung (DSGVO).

Der Code, der eine Zuordnung der pseudonymisierten Daten zu Ihrer Person ermöglicht, wird nur an Ihrem Studienzentrum aufbewahrt. Eine Weitergabe der Daten erfolgt nur in pseudonymisierter oder anonymisierter Form. Für etwaige Veröffentlichungen werden nur die pseudonymisierten oder anonymisierten Daten verwendet. Im Rahmen dieser klinischen Prüfung ist keine Weitergabe von Daten in Länder außerhalb der EU (Drittland) vorgesehen.

Ihre Einwilligung bildet die Rechtsgrundlage für die Verarbeitung Ihrer personenbezogenen Daten. Sie können die Einwilligung zur Erhebung und Verarbeitung Ihrer Daten jederzeit ohne Begründung widerrufen. Nach Ihrem

6 Widerruf werden keine weiteren Daten mehr über Sie erhoben. Die bis zum Widerruf erhobenen Daten können
7 allerdings weiter im Rahmen dieser klinischen Studie verarbeitet werden.

8 Nach der DSGVO stehen Ihnen grundsätzlich die Rechte auf Auskunft, Berichtigung, Löschung, Einschränkung
9 der Verarbeitung, Datenübertragbarkeit und Widerspruch zu, soweit dies die Ziele der klinischen Studie nicht
10 unmöglich macht oder ernsthaft beeinträchtigt und soweit dem nicht andere gesetzliche Vorschriften
11 widersprechen.
12

13 Das gemäß DSGVO vorgesehene Recht auf Löschung Ihrer im Rahmen dieser klinischen Prüfung verarbeiteten
14 Daten steht Ihnen aufgrund von Regelungen nach dem Arzneimittelgesetz und Medizinproduktegesetz nicht zu.
15 Zusätzliche ist bei einer klinischen Prüfung nach dem Arzneimittelgesetz das Recht auf Datenübertragbarkeit
16 außer Kraft gesetzt.
17

18 Die voraussichtliche Dauer der klinischen Studie ist zwei Jahre. Die Dauer der Speicherung Ihrer Daten über das
19 Ende oder den Abbruch der klinischen Studie hinaus ist durch Rechtsvorschriften geregelt.
20

21 Falls Sie Fragen zum Umgang mit Ihren Daten in dieser klinischen Studie haben, wenden Sie sich zunächst an
22 Ihren Prüfarzt. Dieser kann Ihr Anliegen ggf. an die Personen, die für den Datenschutz verantwortlich sind,
23 weiterleiten.
24

25 Kontaktdaten der Datenschutzbeauftragten der an dieser klinischen Studie beteiligten Institutionen:
26

27 Datenschutzbeauftragter des Sponsors: datenschutz@meduniwien.ac.at
28

29 Kontaktdaten der Datenschutzbeauftragten der an dieser klinischen Studie beteiligten Institutionen:
30

31 Name der Datenschutzbeauftragten
32

33 Sie haben das Recht, bei der österreichischen Datenschutzbehörde eine Beschwerde über den Umgang mit Ihren
34 Daten einzubringen (www.dsb.gv.at; E-Mail: dsb@dsb.gv.at).
35

46 12. Entstehen für die Teilnehmer Kosten? Gibt es einen Kostenersatz oder 47 eine Vergütung?

51 Durch Ihre Teilnahme an dieser klinischen Studie entstehen für Sie keine zusätzlichen Kosten. Es ist keine Vergütung
52 vorgesehen.
53

13. Möglichkeit zur Diskussion weiterer Fragen

Für weitere Fragen im Zusammenhang mit dieser klinischen Studie stehen Ihnen Ihr Studienarzt und seine Mitarbeiter gern zur Verfügung. Auch Fragen, die Ihre Rechte als Patient und Teilnehmer an dieser klinischen Studie betreffen, werden Ihnen gerne beantwortet.

Name der Kontaktperson: Name

Erreichbar unter: Telefonnummer

Name der Kontaktperson: Name

Erreichbar unter: Telefonnummer

14. Wo kann ich weitere Informationen einholen?

Name der Patientenanwaltschaft

15. Einwilligungserklärung

8 Name des Patienten:
9

10 Geb.Datum:
11

12 Ich erkläre mich bereit, an der klinischen Studie „**Einfluss von Desfluran versus Sevofluran versus Propofol auf das Auftreten von Delir bei älteren PatientInnen, die sich einer nicht-herzchirurgischen Operation mit mittelgroßem oder großem Risiko unterziehen**“ teilzunehmen. Ich bin darüber aufgeklärt worden, dass ich die Teilnahme ohne nachteilige Folgen, insbesondere für meine medizinische Betreuung, ablehnen kann.
13
14

15 Ich bin von Frau/Herrn (Dr.med.) ausführlich und
16 verständlich über die klinische Studie, mögliche Belastungen und Risiken, sowie über Wesen, Bedeutung und
17 Tragweite der klinischen Studie und die sich für mich daraus ergebenden Anforderungen aufgeklärt worden. Ich
18 habe darüber hinaus den Text dieser Patientenaufklärung und Einwilligungserklärung, die insgesamt 12 Seiten
19 umfasst, gelesen. Aufgetretene Fragen wurden mir vom Prüfarzt verständlich und zufriedenstellend beantwortet.
20 Ich hatte ausreichend Zeit, mich zu entscheiden. Ich habe zurzeit keine weiteren Fragen mehr.
21
22

23 Ich werde den ärztlichen Anordnungen, die für die Durchführung der klinischen Studie erforderlich sind, Folge
24 leisten, behalte mir jedoch das Recht vor, meine freiwillige Mitwirkung jederzeit zu beenden, ohne dass mir daraus
25 Nachteile, insbesondere für meine medizinische Betreuung, entstehen.
26
27

28 Ich stimme ausdrücklich zu, dass meine im Rahmen dieser klinischen Studie erhobenen Daten wie im Abschnitt
29 „Datenschutz“ dieses Dokuments beschrieben verarbeitet werden.
30
31

32 Für den Fall, dass ich aus der klinischen Prüfung ausscheide, bin ich einverstanden, dass meine Proben weiterhin
33 aufbewahrt und analysiert werden, wie in dieser Information und – wenn zutreffend – in den Informationen zu den
34 Substudien beschrieben:
35
36

37 ja

38 nein

39 Eine Kopie dieser Patienteninformation und Einwilligungserklärung habe ich erhalten. Das Original verbleibt beim
40 Prüfarzt.
41
42

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
8010
8011
8012
8013
8014
8015
8016
8017
8018
8019
8020
8021
8022
8023
8024
8025
8026
8027
8028
8029
8030
8031
8032
8033
8034
8035
8036
8037
8038
8039
8040
8041
8042
8043
8044
8045
8046
8047
8048
8049
8050
8051
8052
8053
8054
8055
8056
8057
8058
8059
8060
8061
8062
8063
8064
8065
8066
8067
8068
8069
8070
8071
8072
8073
8074
8075
8076
8077
8078
8079
8080
8081
8082
8083
8084
8085
8086
8087
8088
8089
8090
8091
8092
8093
8094
8095
8096
8097
8098
8099
80100
80101
80102
80103
80104
80105
80106
80107
80108
80109
80110
80111
80112
80113
80114
80115
80116
80117
80118
80119
80120
80121
80122
80123
80124
80125
80126
80127
80128
80129
80130
80131
80132
80133
80134
80135
80136
80137
80138
80139
80140
80141
80142
80143
80144
80145
80146
80147
80148
80149
80150
80151
80152
80153
80154
80155
80156
80157
80158
80159
80160
80161
80162
80163
80164
80165
80166
80167
80168
80169
80170
80171
80172
80173
80174
80175
80176
80177
80178
80179
80180
80181
80182
80183
80184
80185
80186
80187
80188
80189
80190
80191
80192
80193
80194
80195
80196
80197
80198
80199
80200
80201
80202
80203
80204
80205
80206
80207
80208
80209
80210
80211
80212
80213
80214
80215
80216
80217
80218
80219
80220
80221
80222
80223
80224
80225
80226
80227
80228
80229
80230
80231
80232
80233
80234
80235
80236
80237
80238
80239
80240
80241
80242
80243
80244
80245
80246
80247
80248
80249
80250
80251
80252
80253
80254
80255
80256
80257
80258
80259
80260
80261
80262
80263
80264
80265
80266
80267
80268
80269
80270
80271
80272
80273
80274
80275
80276
80277
80278
80279
80280
80281
80282
80283
80284
80285
80286
80287
80288
80289
80290
80291
80292
80293
80294
80295
80296
80297
80298
80299
80300
80301
80302
80303
80304
80305
80306
80307
80308
80309
80310
80311
80312
80313
80314
80315
80316
80317
80318
80319
80320
80321
80322
80323
80324
80325
80326
80327
80328
80329
80330
80331
80332
80333
80334
80335
80336
80337
80338
80339
80340
80341
80342
80343
80344
80345
80346
80347
80348
80349
80350
80351
80352
80353
80354
80355
80356
80357
80358
80359
80360
80361
80362
80363
80364
80365
80366
80367
80368
80369
80370
80371
80372
80373
80374
80375
80376
80377
80378
80379
80380
80381
80382
80383
80384
80385
80386
80387
80388
80389
80390
80391
80392
80393
80394
80395
80396
80397
80398
80399
80400
80401
80402
80403
80404
80405
80406
80407
80408
80409
80410
80411
80412
80413
80414
80415
80416
80417
80418
80419
80420
80421
80422
80423
80424
80425
80426
80427
80428
80429
80430
80431
80432
80433
80434
80435
80436
80437
80438
80439
80440
80441
80442
80443
80444
80445
80446
80447
80448
80449
80450
80451
80452
80453
80454
80455
80456
80457
80458
80459
80460
80461
80462
80463
80464
80465
80466
80467
80468
80469
80470
80471
80472
80473
80474
80475
80476
80477
80478
80479
80480
80481
80482
80483
80484
80485
80486
80487
80488
80489
80490
80491
80492
80493
80494
80495
80496
80497
80498
80499
80500
80501
80502
80503
80504
80505
80506
80507
80508
80509
80510
80511
80512
80513
80514
80515
80516
80517
80518
80519
80520
80521
80522
80523
80524
80525
80526
80527
80528
80529
80530
80531
80532
80533
80534
80535
80536
80537
80538
80